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ABSTRACT 
VITAMIN D, CALCIUM, AND DAIRY CONSUMPTION AND RISK OF EARLY 
MENOPAUSE 
 
MAY 2018 
 
ALEXANDRA C. PURDUE-SMITHE, B.S., UNIVERSITY OF MASSACHUSETTS 
AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Elizabeth R. Bertone-Johnson 
 
  
Early menopause, defined as the cessation of ovarian function before the age of 
45, affects roughly 10% of women in Western populations. Current research suggests that 
women who experience early menopause are at increased risk for cardiovascular disease 
and other adverse health outcomes. Early menopause may also have substantial financial 
and psychological consequences for family planning, particularly as women increasingly 
delay childbearing into the later reproductive years. Emerging research suggests that 
modifiable lifestyle factors such as diet may play an important role in ovarian aging. 
According to our review of the current biologic and epidemiologic literature in Chapter 1, 
vitamin D, calcium, and dairy consumption may be related to the physiologic processes 
involved in ovarian aging. However, no prior epidemiologic studies have evaluated these 
exposures with regard to risk of early menopause. Thus, the aim of this dissertation was 
to evaluate these associations in the prospective Nurses’ Health Study II (NHS2) 
(n=112,429).  
vii 
In Chapter 2, we evaluated how intakes of vitamin D and calcium are associated 
with risk of early menopause. Results of this study suggest that high versus low intakes of 
vitamin D and calcium from food sources, particularly dairy foods, are associated with 
17% and 13% lower risk of early menopause, respectively.  
In Chapter 3, we evaluated how total and free plasma 25-hydroxyvitamin D 
(25(OH)D) and vitamin D binding protein levels (VDBP) are associated with risk of early 
menopause. According to our findings, total and free 25(OH)D levels are not associated 
with risk of early menopause, and VDBP may be positively associated with risk.  
In Chapter 4, we evaluated how intakes of total, low-fat, high-fat, and individual 
dairy foods are associated with risk of early menopause. Findings indicate that high 
versus low intake of low-fat dairy foods is associated with 23% lower risk of early 
menopause. In particular, intakes of skim milk and yogurt intake were associated with 
lower risk of early menopause.  
In conclusion, vitamin D and calcium are not importantly related to early 
menopause risk. Intake of low-fat dairy foods is associated with lower risk of early 
menopause, but findings should be replicated in future studies.  
 
viii 
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CHAPTER 1 
DAIRY CONSUMPTION AND OVARIAN AGING AND REPRODUCTIVE 
LIFESPAN: A NARRATIVE REVIEW 
1.1 Abstract 
Accelerated ovarian aging is characterized by earlier onset of menopause and is 
associated with increased risk of cardiovascular disease, early cognitive decline, and 
other conditions. In addition, accelerated ovarian aging may interfere with family 
planning, particularly as women choose to delay childbearing until the later reproductive 
years. Recent evidence suggests that the rate of ovarian aging is modifiable, particularly 
with regard to dietary factors. Dairy is comprised of several nutritive and non-nutritive 
components that may be functionally related to ovarian aging. This aim of this review 
was to summarize potential biologic mechanisms through which dairy may influence 
ovarian function, systematically evaluate the existing epidemiologic evidence, and 
identify potential questions to be addressed in future studies. Evidence from in vitro and 
animal studies suggest that dairy food intake may be related to ovarian aging through 
pathways related to vitamin D, inflammation, and sex hormones. However, at this time, 
epidemiologic evidence is limited; for example, no studies have evaluated dairy intake 
and early menopause, and only one prospective study has evaluated age at menopause 
with regard to low and high-fat dairy. Results from this study suggest that intake of low-
fat dairy foods, but not high-fat dairy may extend reproductive lifespan, but important 
questions remain. To address current gaps in our understanding of this important topic, 
future prospective studies should examine specific dairy foods, compare associations of 
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dairy intake at different ages, and directly evaluate how dairy relates biologically to 
ovarian function. Findings from these studies will provide a clearer picture of how dairy 
intake may be related to ovarian aging and identify the mechanisms through which dairy 
may influence reproductive lifespan. 
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1.2 Introduction 
Emerging evidence suggests that the duration of a woman’s reproductive lifespan 
is related to risk of chronic diseases. Specifically, a shorter reproductive lifespan, usually 
marked by the early cessation of ovarian function, is associated with increased risk of 
cardiovascular disease, early cognitive decline, and osteoporosis, among other conditions. 
(1–5) Findings from population-based studies indicate that genetic factors do not explain 
the majority of variation in menopausal timing, (6,7) and that modifiable lifestyle factors, 
including diet, may play a role in maintaining normal ovarian function during the third 
and fourth decades of a woman’s life. (8–10) Recent evidence suggests that intake of 
dairy foods may be related to several reproductive outcomes; (11–13) however, to our 
knowledge, no prior reviews have evaluated the existing evidence regarding how dairy 
consumption is associated with ovarian aging and reproductive lifespan. This review 
briefly discusses recent advances in our understanding of the physiology of ovarian 
aging, summarizes potential biologic mechanisms through which dairy may influence 
ovarian function, systematically evaluates the existing epidemiologic evidence, and 
proposes potential avenues of future research to address gaps in our current 
understanding of this important topic. 
1.3 Current Status of Knowledge 
1.3.1 Physiology of ovarian aging 
Ovarian aging refers to the process through which the number and quality of 
follicle-surrounded oocytes present in the ovarian cortex declines as a woman ages. 
(6,14) According to Broekmans et al, at about the fourth month of fetal development, the 
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female ovaries contain roughly 6-7 million oocytes surrounded by granulosa cells, which 
constitute the primordial follicle pool. (6) During the second half of fetal development, 
the majority of primordial follicles undergo apoptosis; at birth, only 1-2 million 
primordial follicles remain in the ovarian cortex. (15) This age-related decline in 
primordial follicles continues through childhood, adolescence, and the reproductive years 
until menopause occurs. At menarche, approximately 300,000 follicles remain, and at the 
onset of menopause, this number is reduced to ~1,000. (16–18)  
During the reproductive years, >99% of primordial follicles are non-growing. (6) 
At any given time, ~20-150 follicles are in the early stages of growth, during which the 
size of the oocytes increase and the granulosa cells of the follicles proliferate. (19,20) The 
small preantral follicles continue to enlarge and the granulosa cells surrounding the 
oocyte develop follicle-stimulating hormone (FSH) receptors until the follicle reaches the 
large antral stage. (19) The development of the antral cavity indicates transition to the 
antral follicle stage, at which point the follicle becomes responsive to FSH. (19) A single 
dominant follicle is then selected and the oocyte is released from the follicle as ovulation 
occurs. After ovulation, the follicle then develops into the corpus luteum. (6) Ovulation is 
followed by fertilization and implantation, or in the absence of fertilization, regression of 
the corpus luteum and endometrial shedding (i.e., menses). (6) As the ovary ages and 
follicle count declines, the quality of oocytes and the follicles that surround the oocytes 
also decline, perhaps increasing the rate of meiotic nondisjunction. (14,20–24)  
Ovarian aging and function are commonly assessed using biomarker measures 
such as anti-Müllerian hormone (AMH), FSH, and antral follicle count (AFC). 
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Assessment of ovarian age via biomarkers has important implications not only for clinical 
understanding of reproductive status and potential, but also for research purposes.  
1.3.1.1 Anti-Müllerian Hormone 
In recent years, anti-Müllerian hormone has been identified as a marker of ovarian 
age and predictor of timing of menopause. AMH is a glycoprotein secreted exclusively 
by the granulosa cells of primary, secondary and small antral follicles of the ovary. (25) 
AMH secretion begins as primordial follicles differentiate to the primary stage and ceases 
once the follicles reach the mid-antral stage, just before cyclic recruitment. (26–28) AMH 
has been well established as a marker of reproductive decline due to its high correlation 
with antral follicle count, which is an indicator of the number of primordial follicles 
remaining in the ovarian cortex. (28–34) As the primordial follicle pool diminishes, 
serum levels of AMH decline until they become undetectable at the onset of menopause. 
(35–38)  
In addition to being a marker of ovarian reserve, recent studies suggest that AMH 
may also influence the rate of ovarian aging by regulating early follicle growth. This 
hypothesis is supported by findings of Durlinger et al, who demonstrated that AMH 
inhibits primordial follicle growth in mice. (26) A subsequent study by the same group 
found that AMH knock-out mice experienced accelerated follicle recruitment and 
premature depletion of ovarian follicles as compared to their wild-type counterparts, and 
that AMH diminishes FSH-stimulated preantral follicle growth in vitro. (27) 
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1.3.1.2 Follicle-Stimulating Hormone 
Assessment of FSH levels may also provide information on ovarian age and 
reproductive potential. Throughout the reproductive years, FSH is responsible for cyclic 
recruitment of antral follicles, follicle development to the pre-ovulatory phase, and 
sensitization of the follicle to luteinizing hormone. (39,40) While FSH levels are variable 
across the menstrual cycle, ovarian aging during the later reproductive years is 
characterized by higher basal levels of FSH during the early follicular phase. (41–43) 
This is primarily due to the decline in inhibin B, a dimeric polypeptide secreted by 
granulosa cells of the antral follicles. (44–46) Ordinarily, inhibin B suppresses FSH 
production by the pituitary gland; however, as the ovarian follicle pool diminishes with 
age, inhibin B correspondingly declines, resulting in higher levels of FSH. (46) The rise 
in FSH results in a shortening of the follicular phase and therefore greater ovulatory 
frequency. (47–49)  
Emerging data suggest that FSH is not only reflective of the age-related decline in 
follicle numbers during the late reproductive years, but may also exert direct effects on 
the acceleration of follicle loss in the years leading up to menopause. McTavish et al 
recently demonstrated that transgenic (tg)-FSH mice <22 weeks of age expressing 
increasing levels of pituitary-independent human FSH experienced higher rates of 
ovulation and larger litter sizes as compared to their wild-type (WT) counterparts. (39) 
However, for mice ≥22 weeks of age, litter sizes were smaller and earlier loss of fertility 
occurred in tg-FSH mice as compared to WT mice. Two important points may be gleaned 
from these data: 1) these findings are consistent with the hypothesis that FSH increases 
rates of ovulation by increasing dominant follicle development, leading to decline in 
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fertility, and 2) that FSH may directly accelerate follicle loss, rather than simply reflect 
the diminishing follicle pool. While these findings have not yet been confirmed in 
humans, they are supported by the paradoxical observation that women with fragile X 
syndrome, which is associated with higher levels of FSH, commonly experience higher 
rates of multiple ovulation (dizygotic twinning), yet earlier onset of menopause. (50–52)  
One of the complicating factors in using FSH as a marker of ovarian aging is that 
basal FSH levels rise during the very late reproductive years, only after a significantly 
proportion of the follicle pool is lost. (6) During the normal menstrual cycle, FSH is 
secreted by the pituitary gland, stimulating follicle growth and production of estradiol by 
granulosa cells. Rising estradiol and progesterone work in a negative feedback loop to 
slow the release of FSH. Correspondingly, as estradiol levels decline, FSH levels 
increase. FSH levels are therefore not only influenced by the size of the follicle pool, but 
also by fluctuations in estradiol, which presents methodologic challenges for 
epidemiologic studies using FSH as a marker of ovarian aging.  
1.3.1.3 Antral Follicle Count 
While AMH and FSH levels serve as proxies for ovarian reserve, AFC provides a 
direct measurement of the size of the oocyte pool. As described earlier, the size of the 
primordial follicle pool declines steadily with age and is indicative of ovarian aging. 
Although the primordial follicles themselves are too small to identify in a clinical setting 
using diagnostic imaging, the primordial follicle pool size is highly correlated with AFC 
throughout the reproductive years. (6,53) Antral follicles are large enough (2-10 mm) to 
be detected by transvaginal sonography imaging, and are sensitive to FSH. (54) As the 
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primordial follicle pool size decreases with age, AFC similarly declines, and is thus a 
reliable measure of ovarian reserve. (53)  
Given that AMH is secreted exclusively by the granulosa cells of the preantral 
follicles, AFC is highly correlated with AMH levels at all ages. As compared to FSH, 
AFC and AMH levels are better predictors of ovarian aging throughout the reproductive 
years because they are able to assess ovarian reserve before a significant decline in 
follicle count has occurred.   
1.3.2 Consequences of accelerated ovarian aging 
 Accelerated ovarian aging is characterized by an increased rate of follicle loss and 
earlier age at menopause. The mean age of menopause in Western populations is 51, 
although the range is fairly wide (~40-60 years). (25) About 10% of women experience 
early natural menopause (i.e., menopause before age 45). (6) Premature ovarian failure 
(POF) affects 1% of women, and is defined as menopause before the age of 40. (6) The 
consequences of accelerated ovarian aging and thus, early menopause or POF are 
substantial. Epidemiologic evidence suggests that women who experience early 
menopause are at increased risk of cardiovascular disease, early cognitive decline, and 
osteoporosis, among other conditions. (1–5) Because women experience an ebb in 
fertility during the 10 years leading up to menopause, early menopause may interfere 
with family planning, which may have serious financial and psychological implications. 
(1,6) 
 Recent studies suggest that ovarian aging and menopausal timing are modifiable – 
specifically, smoking (55–59), diet (8–10,60,61), and BMI (57,62) have been associated 
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with the age at which menopause occurs. With regard to diet, dairy food intake is of 
particular interest, as it has been associated with other reproductive health conditions in 
women, such as endometriosis and premenstrual syndrome. (13,63) The aim of this 
review is to evaluate the potential physiologic mechanisms and epidemiology of dairy 
foods and ovarian aging, specifically.  
1.3.3 Dairy foods and ovarian aging 
According to the USDA, the dairy food group includes as all fluid milk products 
and foods made from milk. (64) Dairy foods are a rich source of micronutrients including 
vitamin D, vitamin B12, calcium, phosphorus, potassium, and magnesium. Macronutrient 
constituents of dairy foods include milkfat, lactose, and whey and casein protein. (65) In 
addition to macro and micronutrients, dairy also contains non-nutritive components, 
including estrogens, progesterone, testosterone, and androstenedione. (66,67)   
Currently, the USDA recommends that women ages 9 years and older consume at 
least three servings of dairy foods per day (e.g., 1 cup of milk or yogurt, or 1.5 ounces of 
natural cheese). (68) Findings from the National Health and Nutrition Examination 
Survey indicate that among women ages 14-18, mean intake of dairy foods is currently 
1.6 servings/day. (69) Intake declines with age, as women in the 19-30 age group 
consume 1.5 servings/day, and women 31-50 years old consume 1.4 servings/day, on 
average. 
Findings of animal and in vitro studies suggest a number of mechanisms through 
which these dairy constituents may directly or indirectly influence ovarian aging, which 
are summarized below.  
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1.3.3.1 Vitamin D  
Fortified milk is an important source of dietary vitamin D; for example, one 8 oz. 
serving provides ~100 IU of vitamin D. (65,70) In fact, fortified dairy products contribute 
more vitamin D to the diets of U.S. adults than any of the other food groups alone. Recent 
systematic reviews have concluded that vitamin D plays a role in conditions related to 
fertility, including polycystic ovary syndrome (PCOS) and in vitro fertilization outcomes; 
however, potential mechanisms explaining such associations remain poorly understood. 
(71,72)  
Vitamin D metabolism has been described in detail previously. (73) Briefly, 
vitamin D may be obtained in one of two ways. The majority of vitamin D is produced 
during periods of solar UVB radiation exposure by cutaneous conversion of 7-
dehydrocholesterol to provitamin D3, which is then isomerized to colecalciferol (vitamin 
D3). A smaller proportion of vitamin D may be obtained through supplements and dietary 
intake of foods that naturally contain or are fortified with vitamin D, as either vitamin D2 
(ergocalciferol) or vitamin D3.  
 Upon ingestion or solar UVB radiation exposure, colecalciferol and 
ergocalciferol are converted to 25-hydroxyvitamin D (25(OH)D) by a-hydroxylase, 
primarily in the liver. 25(OH)D is the primary circulating form of vitamin D, and is later 
hydroxylated in the kidney and other tissues to the active metabolite of the vitamin, 1,25-
dihydroxyvitamin D (1,25(OH)2D). Circulating 1,25(OH)2D then binds to vitamin D 
receptors (VDR) present in many tissues of the body, including the ovary. (74)  
Findings from animal and in vitro studies suggest that vitamin D may play a role 
in ovarian aging, through associations with AMH, FSH and estradiol levels. Malloy et al 
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identified a vitamin D response element (VDRE) in the promoter region of the AMH 
gene, providing evidence that vitamin D has a direct effect on the mRNA expression of 
AMH. (75) Findings from an in vitro study by Krishnan et al indicate that vitamin D 
upregulates AMH mRNA in prostate cells, consistent with the hypothesis that vitamin D 
plays a regulatory role in the expression of AMH. (76) In line with these findings, 
Wojtusik et al observed that vitamin D modulates AMH mRNA expression in a dose-
dependent fashion in the granulosa cells of hen. (77) Specifically, a 100nM dose of 
vitamin D resulted in decreased expression of AMH mRNA among 3-5 mm and 6-8 mm 
follicles. Furthermore, FSH receptor expression and granulosa cells proliferation was 
higher among samples receiving 100nM of vitamin D as compared to the control group.  
The findings of these studies provide compelling evidence of a potential role of 
vitamin D in the expression of AMH and folliculogenesis. It is possible that elevated 
25(OH)D levels contribute to higher circulating 1,25(OH)2D, which binds to AMH gene 
VDRE in the granulosa cells of primary, secondary, and small antral follicles of the 
ovary. This may in turn up-regulate AMH secretion by the granulosa cells and slow 
follicle growth and recruitment, and work to preserve the number of follicles present in 
ovarian cortex, thus prolonging the reproductive lifespan. These findings also raise 
important questions. Given that these were in vitro studies, it is still unclear whether the 
doses tested are physiologically relevant for humans. Moreover, it remains unclear 
whether vitamin D-induced changes in AMH expression and secretion may be sufficient 
to interfere with follicle recruitment in humans or alter menopausal timing. 
 Vitamin D from dairy foods may also be related to ovarian aging through indirect 
effects on circulating FSH levels via estradiol. As described earlier, elevated FSH levels 
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are indicative of ovarian aging, albeit only during the late reproductive years.(78) FSH 
levels are variable across the menstrual cycle, and are influenced by estrogen levels via 
negative feedback. (6) Estrogens including estradiol are produced by aromatization of 
androgen precursors by aromatase (CYP19). (79) and recent in vitro studies have found 
that aromatase activity is altered by 1,25(OH)2D levels in prostate and placental cells and 
osteoblasts. (80,81) Correspondingly, findings of Kinuta et al indicate that aromatase 
activity is suppressed in VDR null mutant mice as compared to WT counterparts, 
suggesting that aromatase activity is sensitive to vitamin D deficiency. (82) It is therefore 
possible that estrogen synthesis may be functionally related to 25(OH)D status through 
effects on conversion of androgen precursors to estrogens by aromatase. (79) In line with 
this hypothesized mechanism, findings from one cross-sectional study of Norwegian 
women suggest that estradiol levels vary significantly according to season, with highest 
levels recorded in June. (83)  
 Because FSH levels are inversely related to estrogen levels, 25(OH)D levels may 
influence levels of estradiol, which have an inhibitory effect on levels of FSH. In light of 
the evidence suggesting that increasing levels of FSH may accelerate ovarian aging, 
vitamin D may work to increase levels of estradiol, which reduces basal FSH levels and 
therefore slows the decline in the follicle pool size during the later reproductive years.  
1.3.3.2 Sex steroids in dairy foods 
Bovine milk contains steroid hormones and growth factors that may also be 
related to ovarian aging including estrogens, progesterone, and androgen precursors. 
Laboratory evidence suggests that milk products contain varying concentrations of 
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conjugated and unconjugated estrogen metabolites. For example, in one study, levels of 
unconjugated estrogen metabolites in skim milk were found to be relatively modest (7.21 
pg/mL), but were higher with increasing milkfat content (51.64 pg/mL for whole milk 
and 273.72 pg/mL for buttermilk). (66) Dairy milk also contains appreciable amounts of 
progesterone; for example, whole milk contains 10 µg of progesterone per liter. (67) 
Because unconjugated estrogen metabolites and progesterone are lipophilic, 
concentrations are considerably higher in full-fat dairy products. (67) However, it is 
important to note that conjugated estrogen metabolites, including estrone sulfate, are 
hydrophilic and thus may be more bioavailable in low-fat dairy products. (66) 
Conjugated estrogen metabolites are considered to be more biologically active than their 
unconjugated counterparts due to circumvention of hepatic metabolism. (84) Importantly, 
these hormones and metabolites have been shown to remain biologically active after 
ingestion, and may induce changes in the hormonal profile. (85) This evidence is further 
supported by findings from an epidemiologic study in which consumption of dairy 
products was significantly positively associated with plasma levels of total and free 
estradiol. (86)  
In addition to estrogen and progesterone, milk also contains androgens that may 
be implicated in ovarian aging, including testosterone and androstenedione. (87) 
Concentrations of these androgens vary, but have been estimated to fall between 0.02-
0.15 µg/L and 0.1-3.5 µg/L, for testosterone and androstenedione, respectively. (87) 
Exogenous androgens have been shown to increase levels of circulating insulin-like 
growth factor 1 (IGF-1) in humans. (88) In fact, four studies have observed that dairy 
intake is associated with significantly higher levels of circulating IGF-1. (89–92) Age is 
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associated with a decrease in circulating IGF-1, (8,93) and studies in rats have observed 
that low IGF-1 is associated with disruption of luteinizing hormone, (93) the hormone 
primarily responsible for ovulation. It is possible that dairy consumption may therefore 
increase levels of IGF-1, allowing for the continuation of normal menstrual cycles during 
the later reproductive years.  
Taken together, these studies provide provocative evidence that the non-nutritive 
components of dairy may alter hormone levels in premenopausal women. It is currently 
unclear, however, whether the fluctuations in steroid hormones associated with dairy 
consumption are sufficient to induce consequential alterations in ovarian function or the 
rate of ovarian aging.  
1.3.3.3 Inflammation 
 Dairy may also play a role in ovarian aging through the modification of 
inflammatory pathways that influence levels of circulating cytokines. Chronic systemic 
inflammation is associated with upregulation of the nuclear factor-kappaB (NF-kB) 
pathway and increased levels of tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6) 
and IL-6-stimulated production of C-reactive protein (CRP) in the liver. (94) A recent 
meta-analysis of genome-wide association studies identified a candidate gene (PRRC2A) 
implicated in both menopausal timing and the NF-kB inflammatory pathway, lending 
support for a potential role of inflammation in ovarian aging. (95) In addition, one study 
observed higher serum and follicular fluid levels of CRP among anovulatory women, as 
compared to ovulatory women, suggesting that the ovaries may be sensitive to such 
markers of inflammation. (96)  
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Emerging evidence suggests that dairy foods have anti-inflammatory properties. 
One recent randomized trial observed that among overweight and obese adults with 
metabolic syndrome, those fed an adequate-dairy diet (>3.5 servings/day) as compared to 
a low-dairy diet (<0.5 servings/day) experienced a significant reduction in levels of 
circulating IL-6 and TNF-a after 12 weeks. (97) Similarly, another randomized cross-
over trial found that among overweight and obese individuals, consuming a dairy-
supplemented versus a eucaloric soy-supplemented diet was associated with significantly 
lower levels of TNF-a and IL-6. (98) In light of this evidence, it is plausible that dairy 
may alter the systemic and ovarian inflammatory milieu, thereby influencing rate of 
ovarian aging.  
Dairy may influence ovarian aging through inflammatory pathways through 
effects on adiposity, and through anti-inflammatory action of vitamin D. The association 
of adiposity and systemic inflammation is well-established, as adipocytes directly 
produce pro-inflammatory cytokines including TNF-a and IL-6, among others. (99) In 
particular, hypertrophy of visceral adipocytes results in the release of pro-inflammatory 
cytokines including IL-6 and TNF-a, suggesting that central adiposity may be more 
inflammatory than subcutaneous adiposity. (94) A recent meta-analysis of randomized 
controlled trials found dairy intake to be associated with a significant reduction in both 
overall fat mass and visceral adiposity. (100) The physiology underlying this association 
is currently unclear, though some have hypothesized specific mechanisms relating to 
milkfat, whey protein, and calcium. (65,101)  
Whole milk contains roughly 34 g/L of fat, about 50% of which is saturated. (102) 
Specifically, the saturated fatty acids most abundant in milk include palmitic acid (16:0), 
 16 
 
stearic acid (18:0), and myristic acid (14:0).(102) Roughly 25% of the fat content of milk 
is comprised of monounsaturated fatty acids including oleic acid (cis 9-18:1) and trans-
palmitoleic acid (trans-9, 16:1). (102) Oleic acid is unique in that the double bond 
position may result in preferential oxidation, relative to other fatty acids, and has been 
shown to accumulate in subcutaneous rather than visceral fat stores. (103,104) Some 
evidence also suggests that trans-palmitoleic acid is associated with lower waist 
circumference and BMI. (105) Oleic and trans-palmitoleic acid in dairy may divert fat 
deposition to the subcutaneous rather than the visceral adipocytes, resulting in lower 
systemic levels of pro-inflammatory cytokines including CRP.   
Milk also contains roughly 34 g/L of protein, which is comprised of 80% casein 
protein and 20% whey protein. (106) In particular, whey protein may be relevant to the 
adiposity-inflammation relation with ovarian aging due to anti-obesogenic properties. To 
that extent, whey protein contains peptides including lactokinins, which act as 
angiotensin converting enzyme (ACE)-inhibitors. (107) Ordinarily, angiotensin II 
hormone increases adipocyte lipogenesis through upregulation of fatty acid synthase 
expression (108); however, in vitro studies have found that in the presence of whey 
protein, ACE is inhibited, (107) leading to suppression of angiotensin II hormone, and 
thus decreased endogenous fat production. (101) These findings are further supported by 
studies that have found whey protein to be effective in reducing weight while retaining 
lean body mass. (109) According to this evidence, it is possible that whey protein in dairy 
may inhibit adipocyte lipogenesis, resulting in reduced adiposity and levels of the 
inflammatory cytokines implicated in ovarian aging.  
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 Dairy is also an excellent source of calcium; for example, each 8 oz. serving of 
milk contains ~30% of the RDA for women ages 19 and older. (110) Findings from a 
number of epidemiologic studies suggest that intake of calcium, particularly from dairy, 
is inversely associated with adiposity. (111–113) Zemel et al. propose that the mechanism 
responsible for the anti-obesegenic effect of calcium relates to the role of intracellular 
calcium in adipocyte metabolism – specifically, the modulation of adipocyte triglyceride 
stores. (114) The authors note that dietary calcium intake suppresses calcitrophic 
hormones involved in adipocyte fat storage, such as parathyroid hormone. (114) 
Suppression of these hormones may result in lower overall adiposity and adiposity-
induced inflammatory cytokines.  
Collectively, the above evidence suggests a complex interplay of dairy 
components that may contribute to lower overall and central adiposity, thus protecting 
against chronic inflammation characterized by elevated levels of IL-6, TNF-a and IL-6-
induced CRP. Some (31,34,57,62,115–121), but not all (122) studies have observed 
associations of BMI and adiposity and menopausal timing. In light of the evidence 
suggesting that the ovary is sensitive to these inflammatory cytokines, it is possible that 
dairy may protect against ovarian aging by altering the adiposity-mediated inflammatory 
pathway.  
 In addition to associations with AMH and FSH, vitamin D from milk products 
may also influence reproductive lifespan through the modulation of immune pathways. 
Vitamin D plays a multifunctional role in the immune pathways involved in 
inflammation; in particular, it has been shown to inhibit of T cell proliferation and 
monocyte activity. (123) One of the key roles of immune-helper T cells is to secrete 
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inflammatory cytokines including TNF-a. (123) Studies have shown that in the presence 
of vitamin D, T cell proliferation is suppressed, (124) which may in turn down-regulate 
secretion of TNF-a. Likewise, monocytes are responsible for production of IL-6, IL-1, 
IL-8, and TNF-a (123) and contain VDR, which mediate the biologic activity of 
1,25(OH)2D. (73) Human monocyte activity has been shown to be inhibited in the 
presence of vitamin D in vitro, resulting in attenuated secretion of these inflammatory 
cytokines. (125)  
These laboratory data are supported by epidemiologic evidence suggesting a 
direct link between circulating vitamin D and inflammatory factors including TNF-a and 
CRP. (126,127) For example, results from one cross-sectional study indicate that 
25(OH)D levels are inversely associated with TNF-a concentrations. (126) A subsequent 
study by Ngo et al observed a similar inverse relationship of 25(OH)D and CRP levels. 
(127) Given the potency of vitamin D in fortified milk, it is possible that dairy may 
influence ovarian aging in part through immunomodulatory effects of vitamin D that 
reduce chronic systemic inflammation. In fact, in recent years, vitamin D has been 
consistently associated with a number of conditions related to immune dysfunction 
including multiple sclerosis, (128) rheumatoid arthritis, (129) and inflammatory bowel 
disease. (130) 
1.4 Epidemiologic Evidence: Dairy Foods and Reproductive Lifespan 
Despite strong evidence from laboratory and animal studies, relatively few 
epidemiologic studies have evaluated menopause timing and ovarian aging with respect 
to dairy consumption. A number of other studies have evaluated dairy and other 
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conditions potentially related to ovarian aging, though it is unclear whether the 
pathophysiologies underlying these conditions are relevant to the mechanisms of 
reproductive aging. The results of these epidemiologic studies are largely inconsistent, 
but conflicting findings may be explained by differences in population characteristics and 
endpoints studied, as well as potential confounding by dietary components and lifestyle 
factors.   
1.4.1 Dairy and menopause timing 
Perhaps the strongest evidence for a potential role of dairy in ovarian aging comes 
from a prospective study by Carwile et al, which evaluated age at natural menopause in 
relation to intakes of low-fat and high-fat dairy, skim and whole milk, dairy fat and 
protein, calcium, vitamin D, and lactose. (8) Participants included 46,059 premenopausal 
women enrolled in the prospective Nurses’ Health Study (NHS) who were ages 30-55 at 
baseline in 1976. Intakes of the aforementioned exposures were measured using food 
frequency questionnaires (FFQs) every 4 years, and age at menopause was measured via 
self-report of cessation of menses on biennial questionnaires.  
In multivariable analyses limited to premenopausal women less than 51 years of 
age, those who consumed >3 versus 0.1-1 servings/d of low-fat dairy foods experienced 
significantly lower risk of natural menopause occurring in the next month (Hazard ratio 
(HR): 0.86; 95% confidence interval (CI): 0.77-0.96; P-trend <0.001). Skim milk was 
similarly associated with lower risk among the women of the same age group (>6 
servings/wk vs. 0-1 servings/mo HR: 0.93; 95% CI: 0.89-0.97; P-trend <0.001), while 
lactose, dairy fat, and dairy protein were modestly associated with lower risk. 
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Alternatively, intakes of high-fat dairy and whole milk were not associated with risk and 
findings for all foods were null among women ≥51 years of age.  
 More recently, Purdue-Smithe et al evaluated intakes of vitamin D and calcium 
and risk of early menopause among 86,234 premenopausal women enrolled in the 
Nurses’ Health Study II (NHS2). (60) Participants were 25-42 at baseline in 1989 and 
responded to biennial questionnaires and FFQs administered every four years. Although 
researchers did not evaluate dairy foods directly, they observed that vitamin D intake 
from food sources, particularly dairy sources, was associated with significant lower risk 
of early menopause (dairy vitamin D Q5 vs. Q1 HR: 0.85; 95% CI: 0.74-0.98) after 
adjustment for risk factors of early menopause. Calcium intake from dairy sources was 
similarly associated with lower risk of early menopause (Q5 vs. Q1 HR: 0.87; 95% CI: 
0.75-1.00; P-trend=0.03).  
A third study prospectively evaluated the relationship of total dairy intake and age 
at natural menopause among 5110 premenopausal women of the European Investigation 
into Cancer and Nutrition (EPIC)-Heidelberg who were at least 35 years at baseline.(131) 
Total dairy intake was measured using a baseline FFQ, and self-reported age at 
menopause was defined as 12 consecutive months of amenorrhea not due to surgery. 
Results of multivariable analyses indicated no significant association of total dairy intake 
and age at menopause comparing the lowest versus the highest quartile (HR: 1.04; 95% 
CI: 0.86-1.27; P-trend = 0.998).  
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1.4.2 Dairy and other endpoints 
Information from additional studies of dairy and other endpoints related to 
ovarian function such as AFC, POF, and infertility may also be relevant to understanding 
the relation of dairy and ovarian aging, although most of these studies were conducted 
among clinical populations, and it is unclear whether the physiologic mechanisms that 
underlie these conditions are similar.  
1.4.2.1 Antral follicle count 
Two studies have evaluated AFC in relation to dairy protein consumption. 
(132,133) A recent cross-sectional study by Souter et al reported an inverse association of 
dairy protein intake and AFC among women aged 18-45 years who were seeking 
treatment for infertility. (132) After adjusting for potential confounders, women in the 
highest quintile (range = 5.24-9.27% of energy) of dairy protein intake had 14.4% (95% 
CI: 3.9%-23.7%; P<0.01) lower AFC as compared to women in the lowest quintile (range 
= 0-2.31% of energy). These findings are consistent with a randomized trial of 
cynomolgus macaques, an established model for menopause in humans. (133) In this 
trial, 61 monkeys were randomly assigned to either a casein-lactalbulmin (dairy protein-
based) diet or a eucaloric soy protein diet. After 32 months of the experimental diets, the 
monkeys fed the casein-lactalbumin diet had significantly fewer primordial, primary and 
secondary follicles (P<0.05), as compared to those in the soy protein diet arm.  
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1.4.2.2 Premature ovarian failure 
To our knowledge, only one study has evaluated dairy intake in relation to POF. 
(134) In this small (n=160) case-control study, researchers observed no association of 
total dairy intake and POF (5.3 versus 5.6 times/week for cases and controls, 
respectively; P=0.5).  
1.4.2.3 Infertility and anovulation 
Studies of infertility and anovulation in relation to dairy consumption may also be 
relevant to ovarian aging. In a recent prospective study by Chavarro et al, researchers 
examined intakes of dairy foods and anovulatory infertility among 18,555 premenopausal 
women enrolled in the NHS2. (11) Interestingly, intake of low-fat dairy foods was 
associated with increased risk of anovulatory infertility (≥2 vs. ≤1 servings/d Relative 
risk (RR): 1.85; 95% CI: 1.24-2.77; P-trend=.002), whereas intake of high-fat dairy was 
associated with lower risk (≥1 vs. ≤1 servings/d RR: 0.73; 95% CI: 0.52-1.01; P-
trend=0.01). The positive association of low-fat dairy with anovulatory infertility appears 
to be driven, at least in part, by yogurt intake; according to their findings, for each 
additional serving/d, risk of anovulatory infertility increased by 34% (95% CI: 1.02-1.74; 
P-trend=0.03). Likewise, the inverse association observed for high-fat dairy appears to be 
driven by intake of whole milk (RR for each 1 serving/d increase: 0.46; 95% CI: 0.25-
0.84; P-trend=0.01). Estimates for both high and low-fat dairy foods were stronger 
among women older than 32 years, and among women with clinical manifestations of 
PCOS. 
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In another prospective study, Afeiche et al found that among women older than 35 
years, total dairy intake was positively associated with live birth rate (quintile 1 live birth 
rate=16% versus quintile 4 live birth rate=53%; P=0.02), but was unrelated to probability 
of pregnancy or implantation. (135) An additional case-control study of female infertility 
(any cause), reported that women who drank >3 glasses/d of milk (fat content not 
specified) experienced 70% (95% CI: 0.1-0.7) lower odds of infertility, as compared to 
those who consumed no milk among agricultural workers in Wisconsin. (136)  
In line with the findings of Chavarro et al, a small prospective study by Kim et al 
also reported a positive association of yogurt intake and sporadic anovulation among 259 
healthy premenopausal women 18-44 years. (137) In this study, women who consumed 
>0 servings/d of yogurt experienced more than 2-fold risk of sporadic anovulation as 
compared to women who consumed no yogurt (RR=2.1; 95% CI=1.2-3.7). However, 
researchers also observed increased risk of anovulation among women who consumed 
cream, whereas intake of low-fat dairy, high-fat dairy, and other dairy foods were not 
associated with risk.  
1.4.3 Synthesis of the evidence 
 Although the results of these epidemiologic studies are largely inconsistent, a 
number of potential contributing factors may explain, at least in part, the differences in 
findings. First, it is important to note that most of these studies evaluated different 
endpoints. It is currently unclear whether dairy may influence the underlying 
pathophysiologies of POF, infertility, and anovulation in a similar manner to ovarian 
aging and menopause timing. For example, POF represents an extreme end of the ovarian 
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aging spectrum and is strongly related to autoimmunity and genetic factors.(6) Risk of 
conditions like POF may thus be less modifiable than menopause timing in healthy 
premenopausal women.  
 The opposite directions of findings for high and low-fat dairy in relation to 
menopause timing and infertility and anovulation also raise questions about the potential 
influence of PCOS. PCOS is characterized by proliferation of small antral follicles, 
chronic anovulation and infertility. (138,139) Evidence suggests that women with PCOS 
have higher AMH levels due to increased antral follicle proliferation. (140,141) 
Consistent with the mechanisms involved in ovarian aging, some epidemiologic studies 
have observed that women with PCOS experience slower decline in AMH levels 
throughout the reproductive years, (142–144) and later age at menopause. (145)  
~75-80% of women exhibit hyperandrogenism-related characteristics of PCOS 
including hirsutism and overweight/obesity, whereas ~20% are asymptomatic except for 
demonstrated subfertility due to chronic anovulation. (146) Because the diagnostic 
criteria for PCOS vary and depend largely upon the exhibition of phenotypic 
characteristics, (146) it stands to reason that the true prevalence of PCOS in the general 
population and especially in populations seeking treatment for infertility is likely higher 
than what is generally reported. At this time, studies of diet – particularly dairy intake – 
and PCOS are scarce, making it difficult to postulate how dairy, PCOS, and menopause 
timing may be interrelated. However, observations of stronger associations for specific 
dairy foods and anovulatory infertility among women with PCOS in the Chavarro et al 
study suggest that perhaps low-fat dairy is positively associated with risk of PCOS and 
high-fat dairy is associated with lower risk. (11) In light of evidence suggesting a relation 
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of PCOS and menopause timing, future studies evaluating dairy and menopause timing 
should carefully consider potential confounding and mediation by PCOS.  
Second, it is unclear whether clinical endpoints are relevant and generalizable to 
healthy populations of premenopausal women. Epidemiologic studies evaluating 
menopausal timing with respect to dairy intake were conducted among healthy 
premenopausal women, whereas many of the studies evaluating other endpoints were 
conducted among women seeking treatment for infertility. As highlighted above, the 
potential influence of confounding by PCOS, especially in populations seeking treatment 
for infertility is high and warrants additional examination of the relationship of dairy and 
PCOS.  
Third, many of the studies reviewed above evaluated different characteristics of 
dairy foods, which may have important implications regarding potential physiologic 
mechanisms. For instance, studies that separately evaluated high-fat versus low-fat dairy 
reported significant associations with their respective outcomes, (8,11) whereas studies 
evaluating only total dairy intake were null. (131) Although Greenlee et al observed a 
significant inverse association of total milk intake and infertility, their study population 
likely consumed mostly whole milk because the women who comprised the study sample 
were agricultural and dairy farmers. (136) The discordant findings of studies evaluating 
total dairy versus high and low-fat dairy may be explained by differences in hormonal 
mechanisms involving estradiol, progesterone, and androgen precursors in milk and their 
relative bioavailability contingent upon fat content.  
The inverse associations of dairy protein intake and antral follicle count observed 
by 2 studies suggest that dairy protein, specifically, is associated with increased rate of 
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ovarian aging, (133,135) although it is currently unclear whether crude intake of dairy 
protein or relative intake of dairy protein versus other types of protein are more relevant. 
For example, in the Appt et al trial, monkeys in the casein-lactalbumin group were not 
fed dairy products per se, but rather isolated dairy protein. (133) Because there was no 
true control group of monkeys who adhered to a “normal” diet, results indicate only that 
the soy protein versus casein-lactalbumin diet is protective against ovarian aging in 
monkeys; it is unknown how a casein-lactalbumin diet would perform in relation to a 
“typical” diet. Given recent findings from one study that vegetable protein intake was 
associated with lower risk of early menopause, but animal protein was not, (61) it seems 
likely that the Appt findings may be attributed to the relative comparison of dairy versus 
soy protein.  
Finally, Carwile et al’s observation of a significant inverse associations of low-fat 
dairy and skim milk intake with age at menopause in women younger than 51 years of 
age, but not older women, suggests that a window of vulnerability may exist. (8) Nagel et 
al did not stratify estimates for total dairy and menopause according to age, presumably 
due to the lower power of their analysis. (131) If age does indeed modify the dairy-
menopause timing relation, then failure to evaluate age-specific associations may partly 
explain differences in findings of these two studies.  
As a whole, epidemiologic studies conducted to date raise a number of interesting 
questions and issues for consideration in future research. First, because observed 
associations for dairy and menopause timing appear to be modest, large prospective 
studies are necessary to ensure adequate statistical power for overall and stratified 
analyses. Second, to increase the generalizability of findings, future studies should 
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evaluate dairy and ovarian aging among populations of healthy premenopausal women, 
rather than limiting investigations to clinical populations. Third, because the relation of 
dairy, PCOS, and ovarian aging remains unclear, researchers should carefully consider 
the potential influence of PCOS on the dairy-ovarian aging relation. Finally, it appears to 
be important to separately evaluate high and low-fat dairy intake, as well as individual 
dairy constituents.   
 
1.5 Conclusion 
While laboratory evidence supports a plausible role for dairy in delaying ovarian 
aging, the epidemiologic evidence remains limited at this time. Future prospective studies 
that address the methodologic limitations of prior studies will be better equipped to 
answer the following questions: 
• How are specific dairy nutrients (i.e., vitamin D, calcium, protein, fat, and 
lactose) related to ovarian aging? 
• Does dairy intake in childhood, adolescence or early adulthood differentially 
influence rate of ovarian aging compared to intake in later reproductive years? 
• How is dairy intake, PCOS, and ovarian aging interrelated? 
Answers to these questions will provide a clearer picture of how dairy intake may be 
related to ovarian aging and through what mechanisms dairy may influence reproductive 
lifespan. 
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CHAPTER 2 
VITAMIN D AND CALCIUM INTAKE AND RISK OF EARLY MENOPAUSE 
2.1 Abstract 
Early menopause, defined as the cessation of ovarian function before the age of 
45, affects roughly 10% of women and is associated with higher risk for cardiovascular 
disease, osteoporosis and other conditions. Few modifiable risk factors for early 
menopause have been identified, but emerging data suggest that high vitamin D intake 
may reduce risk. We evaluated how intakes of vitamin D and calcium are associated with 
incidence of early menopause in the prospective Nurses’ Health Study II. Intakes of 
vitamin D and calcium from foods and supplements were measured every 4 years by food 
frequency questionnaire. Cases of incident early menopause were identified from 
amongst all participants who were premenopausal at baseline in 1991; over 1.13 million 
person-years, 2,041 women reported natural menopause before age 45. We used Cox 
proportional hazards regression to evaluate relations between intakes of vitamin D and 
calcium and incident early menopause, accounting for potential confounding factors.  
After adjusting for age, smoking, and other factors, women with the highest intake of 
dietary vitamin D (quintile median=528 IU/d) had a significant 17% lower risk of early 
menopause compared to those with the lowest intake (quintile median=148 IU/d; HR: 
0.83; 95% CI=0.72, 0.95; P-trend=0.03). Dietary calcium intake in the highest quintile 
(median=1,246 mg/d) versus the lowest (median=556 mg/d) was associated with 
borderline significant lower risk of early menopause (HR: 0.87; 95% CI: 0.76, 1.00; P-
trend=0.03). Associations were stronger for vitamin D and calcium from dairy sources 
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than from non-dairy dietary sources, whereas high supplement use was not associated 
with lower risk. Findings suggest that high intake of dietary vitamin D and calcium may 
be modestly associated with lower risk of early menopause. Further studies evaluating 
25-hydroxyvitamin D levels, other dairy constituents and early menopause are warranted. 
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2.2 Introduction 
 Early menopause, defined as the cessation of ovarian function before the age of 
45, affects roughly 10% of women in Western populations. (1) Current research suggests 
that women who experience early menopause are at increased risk for premature 
mortality and cognitive decline, osteoporosis, and cardiovascular disease, among other 
adverse health outcomes. (2–5) Women commonly experience an ebb in fertility during 
the 10 years leading up to natural menopause; for women who have early menopause, 
this may have substantial financial and psychological consequences for family planning, 
particularly as women increasingly delay childbearing into the later reproductive years. 
(1,6) Genetic factors do not fully account for the age at which menopause occurs, and 
emerging research suggests that modifiable lifestyle factors such as diet may play an 
important role in ovarian aging. (8,9,120,121,131,147–149) 
Calcium and vitamin D have been implicated in several gynecologic and 
reproductive conditions including polycystic ovary syndrome, endometriosis, and 
premenstrual syndrome, and appear to play a role in fertility. (13,63,150–153) Laboratory 
evidence suggests that the ovary is a target organ for 1,25(OH)2D3, the active metabolite 
of vitamin D3, and that vitamin D receptors (VDR) are expressed in reproductive tissues 
including the ovary. (154,155) Recently, one group observed that plasma 25-
hydroxyvitamin D (25(OH)D) levels were positively associated with ovarian reserve, 
providing further evidence of a protective role of vitamin D on ovarian aging. (156) 
Despite biologic plausibility, to our knowledge, no epidemiologic studies have 
specifically investigated the relation of vitamin D and calcium with incident early 
menopause. One recent prospective study of total vitamin D and calcium intake and 
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overall age at natural menopause among premenopausal women enrolled in the Nurses’ 
Health Study (NHS) found that high intake of low-fat dairy foods, but neither total 
calcium nor total vitamin D intake were associated with later menopause. (8) Importantly, 
because the mean age at the beginning of follow-up for these women was 51.5, the 
relation of vitamin D and calcium intake and risk of early menopause (<45 years old) 
remains unclear. Further, this study did not distinguish calcium and vitamin D from 
dietary versus supplemental sources, which has proven to be an important distinction in 
prior studies of reproductive-related conditions and other outcomes. (13,157,158) 
The aim of this study was to examine the relation of intakes of vitamin D and 
calcium from supplemental, dietary, dairy, and non-dairy dietary sources and subsequent 
risk of early menopause in the prospective Nurses’ Health Study II (NHS2). We 
hypothesized that among participants of the NHS2, total intakes of vitamin D and 
calcium would be inversely associated with early menopause. We similarly hypothesized 
that vitamin D and calcium intake from supplements, food, and dairy would each be 
inversely associated with early menopause.  
2.3 Subjects and Methods 
The NHS2 is a prospective study of 116,430 female U.S. registered nurses who 
were 25-42 years old in 1989 when they responded to a mailed baseline questionnaire. 
Information regarding lifestyle behaviors and medical conditions are collected through 
biennial questionnaires, for which the follow-up rate for each cycle has been at least 89%. 
The study protocol was approved by the Institutional Review Board at Brigham and 
Women’s Hospital in Boston, MA.  
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2.3.1 Assessment of early menopause 
On the 1989 baseline questionnaire, nurses were asked if their periods had ceased 
permanently with the following response options: 1) No: Premenopausal; 2) Yes: No 
menstrual periods; 3) Yes: had menopause but now have periods induced by hormones; 
and 4) Not sure; (e.g., started hormones prior to cessation of periods). Nurses who 
indicated that their periods had ceased were then asked the following questions: 1) At 
what age did your periods cease? (open response); and 2) For what reason did your 
periods cease? (response options were surgery; radiation or chemotherapy; and natural). 
Additionally, women were asked about their current and past use of replacement sex 
hormones. These questions were then repeated on all subsequent questionnaires. Age at 
natural menopause was defined as age after 12 consecutive months of amenorrhea not 
due to radiation, chemotherapy or surgery. A small number of women reported being 
postmenopausal on one questionnaire and then subsequently reported being 
premenopausal. For these women, we defined age at menopause as age after which 
periods were absent for 12 months or more, and then confirmed that this status persisted 
for at least 3 consecutive questionnaires.  
Because we were interested in prospectively evaluating the relationship of vitamin 
D and calcium with incident early menopause, participants were eligible for inclusion in 
our study if they indicated being premenopausal and reported no age at menopause on the 
baseline 1989 questionnaire (n = 108,812). We further excluded women who did not 
respond to or who reported implausible caloric intake (<500 or ≥3,500 kcal/d) on the 
1991 food-frequency questionnaire (FFQ) (n = 21,904), were diagnosed with cancer 
before 1991 (n = 391), or whose date of menopause was before their return date of the 
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1991 FFQ (n = 283). After baseline exclusions, 86,234 women remained in the study 
sample. 
Women were then followed prospectively until 2011 for self-report of the 
cessation of menses, as defined above, or first report of hysterectomy, bi-lateral or 
unilateral oophorectomy, cancer (not including non-melanoma skin cancer), loss to 
follow-up, or death. We identified cases of early menopause as women who reported 
natural menopause before the age of 45.  
2.3.2 Dietary assessment 
Nurses completed validated semi-quantitative FFQs in 1991, 1995, 1999, 2003, 
2007, and 2011, which assessed their average intake of 131 foods, beverages, and 
supplements over the preceding year. (159–161) Each questionnaire asked participants to 
estimate, on average, how often they consumed specific foods and beverages. Participants 
reported their consumption by indicating one of nine frequency categories for each food 
and beverage (i.e., <1 serving/month, 1-3 servings/month, 1, 2-4, 5-6 servings/wk, and 1, 
2-3, 4-5, and ≥6 servings/d). Calcium intake from food sources was estimated by 
summing calcium content per 1 serving of each food and beverage (i.e., skim, low-fat, 
and whole milk, yogurt, hard cheese, cottage cheese, spinach, etc.) and multiplying it by 
the frequency of consumption. Intakes of vitamin D, vegetable protein, and alcohol were 
derived similarly. We calculated percentage of total calories from vegetable protein by 
multiplying grams of vegetable protein by 4 kcal/g and then dividing by total kcal.  
Nurses were queried about average use and dosage of multivitamins, calcium and 
vitamin D supplements every two years on FFQs or biennial questionnaires, from which 
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we estimated intakes of each nutrient from supplement sources. Total vitamin D and 
calcium intakes were then estimated by summing dietary intakes and supplemental 
intakes of each nutrient. Intakes of all nutrients were adjusted for total energy using the 
residual method. (162) 
The validity of the FFQ was assessed by a comparison to 1-week diet records 
among a random subset (n = 100) of women in the Nurses’ Health Study, a comparable 
population of female health professionals. The de-attenuated Pearson correlation 
coefficient comparing the two methods for calcium intake was 0.75. (159) 
2.3.3 Assessment of covariates 
Information regarding age, height, ethnicity, maternal and paternal education 
level, and age at menarche was collected at baseline in 1989. Updated information on 
weight, parity, oral contraceptive use, breastfeeding, hormone therapy use, and smoking 
were collected biennially throughout follow-up. Baseline height and updated weight were 
used to calculate updated body mass index (BMI) as weight (kg)/ height (m)2 for each 
questionnaire cycle. Physical activity was assessed in 1991, 1997, 2001, 2005, and 2009 
using nurses’ responses to questions regarding average time spent per week participating 
in specific activities (i.e., walking, running, biking, etc.), from which we calculated 
metabolic equivalent task (MET)-hours per week. (163) For covariates with missing data, 
we assigned missing values to a missing indicator category. Results from analyses 
restricted to women with complete covariate data (n = 1,956) were identical; we have 
thus presented results from analyses using missing indicator categories to maximize 
statistical power.   
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2.3.4 Statistical analysis 
 We divided participants into quintiles of intake of total (foods + supplements), 
dietary (foods only), and dairy (dairy foods only) vitamin D and calcium according to the 
distribution of the NHS2 population. For supplemental vitamin D and calcium, we 
categorized participants according to their specified dosage (0, 1-599, and ≥600 IU/day 
for vitamin D; 0, 1-399, 400-899, and ≥900 for calcium), with non-users serving as the 
referent group. We additionally dichotomized participants according to the adequacy of 
their total vitamin D and calcium intake based on current Recommended Daily 
Allowances (RDA) (i.e., 600 IU/day for vitamin D; 1,000 mg/day for calcium) in order to 
aid in the interpretability of analyses. Baseline characteristics of our study sample 
according to total calcium and vitamin D intake were assessed using age-adjusted 
generalized linear models. 
 For our primary analyses, we used Cox proportional hazards regression to 
estimate age-adjusted and multivariable hazard ratios (HR) for early menopause by level 
of vitamin D and calcium intake. Tests for linear trend were conducted by modeling the 
median of each category as a continuous variable. For each participant, accrual of follow-
up (in months) began on the date of return of the 1991 questionnaire and continued until 
menopause, first report of hysterectomy, bi-lateral or unilateral oophorectomy, cancer 
(not including non-melanoma skin cancer), loss to follow-up, or death, whichever 
occurred first. Analyses were stratified on age (in months) and questionnaire cycle.  
For each nutrient, we modeled timing of intake in three ways: 1) baseline (1991) 
intake only; 2) simple updating of intake every 2 years; and 3) cumulative average intake. 
Cumulative average values for each exposure were calculated as mean intakes estimated 
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from all FFQs up to and including the cycle prior to menopause. Results from these three 
methods were similar, and because the cumulative average method is suggested to best 
represent long-term dietary intake by reducing misclassification due to within-person 
variation, we have presented only the results from cumulative average models. (164) 
In addition to analyses adjusting only for age, we fit a full multivariable model 
adjusting for variables including age, pack-years of smoking, BMI, parity, lifetime 
duration of breastfeeding, age at menarche, physical activity, percentage of total calories 
from vegetable protein, and alcohol intake (MV1). Because none of the covariates tested 
were associated with a >10% change in exposure hazard ratios, covariate selection was 
based on factors identified a priori (i.e., age, smoking, BMI, parity, age at menarche, and 
physical activity) and factors associated with early menopause in our population (i.e., 
duration of breastfeeding and intakes of alcohol and vegetable protein). To account for 
the high correlation of vitamin D and calcium intakes, we mutually adjusted vitamin D 
for calcium and vice-versa, and supplemental intake for dietary intake and vice-versa in a 
second multivariable model. 
 To investigate potential variation in the associations by timing of exposure, we 
then evaluated whether vitamin D and calcium intake at age 35 versus at age 40 were 
differently associated with early menopause using logistic regression. Because not all 
participants completed questionnaires at exactly ages 35 or 40, dietary exposures and 
covariates on the questionnaire completed closest in time before age 35 and 40 were 
used. These analyses were restricted to women for whom diet data were available at both 
ages 35 and 40, and evaluated risk of early menopause from age 40 to <45 years (n = 
534).  
 37 
 
Because vitamin D is sequestered in adipose tissue (165) and BMI might 
plausibly behave as an effect modifier, we additionally tested the multiplicative 
interaction of BMI (3 categories) and dietary vitamin D (continuous quintile medians) on 
risk of early menopause using cross-product terms. We also conducted a number of 
sensitivity analyses to evaluate the stability of the estimates. First, in order to ensure the 
adequacy of our control for confounding by smoking, we restricted our sample to never 
smokers (n for analysis = 1,533 cases). Second, to evaluate the degree to which 
misclassification of early menopause may have occurred in our study, we additionally 
conducted analyses excluding non-cases who experienced menopause before age 48. We 
were also concerned that conditions indicated for hysterectomy that are also related to 
vitamin D and calcium intake may selectively exclude non-cases with low intake of these 
nutrients. To evaluate this potential selection bias, we conducted a sensitivity analysis 
censoring at date of laparoscopy-confirmed endometriosis and ultrasound-confirmed 
uterine fibroid diagnosis (n for analysis = 1,996 cases). 
All statistical analyses were conducted with SAS v9.4 software (SAS Institute 
Inc., Cary, NC). We used two-sided statistical tests performed at the 0.05 significance 
level for all analyses. 
 
2.4 Results 
 Over 1.13 million person-years of follow-up, 2,041 women experienced incident 
early menopause. Baseline age-adjusted descriptive statistics according to quintile of total 
vitamin D and calcium are presented in Table 2.1. On average, women who had the 
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highest intakes of calcium and vitamin D were younger, more physically active, had 
lower BMI, drank less alcohol and were less likely to be current smokers as compared to 
women with the lowest intakes.  
 Results from analyses of vitamin D intake are presented in Table 2.2. In age-
adjusted analyses, total vitamin D intake was not associated with early menopause (HR: 
0.95; 95% CI: 0.83, 1.09; P-trend = 0.80). Supplemental vitamin D intake ≥600 IU/d was 
also not associated with risk (HR: 1.30; 95% CI: 0.94, 1.78; P-trend = 0.23), while 
intakes of vitamin D from dietary and dairy sources were associated with lower risk of 
early menopause (HR: 0.79; 95% CI: 0.69, 0.91; P-trend <0.01 and HR: 0.82; 95% CI: 
0.71, 0.94; P-trend = 0.02, respectively). For reference, this level of vitamin D intake 
from dairy sources corresponds to roughly 2.5 8-ounce servings of vitamin D-fortified 
milk per day. Intake of non-dairy dietary vitamin D was not associated with risk of early 
menopause (Q5 vs. Q1 HR: 0.94; 95% CI: 0.81, 1.07; P-trend = 0.32).  
After further adjusting for risk factors for early menopause, estimates were similar 
to those of age-adjusted models. For example, in our first multivariable model (MV1) 
controlling for age, BMI, smoking and other risk factors, total vitamin D intake in the 
highest versus lowest quintile was not associated with risk of early menopause (Q5 vs. 
Q1 HR: 0.99; 95% CI: 0.86, 1.13; P-trend = 0.76). Women with dietary vitamin D intake 
in the highest versus the lowest quintile were 17% (95% CI: 0.72, 0.95; P-trend = 0.03) 
less likely to experience early menopause. To evaluate to whether this association may be 
driven by intake of these nutrients from dairy foods, we ran MV1 separately evaluating 
dairy versus non-dairy dietary vitamin D. The HR comparing the highest versus lowest 
quintiles of dairy vitamin D intake was 0.85 (95% CI: 0.74, 0.98; P-trend = 0.06), 
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whereas non-dairy dietary vitamin D was not associated with risk (Q5 vs. Q1 HR: 0.97; 
95% CI: 0.84, 1.12; P-trend = 0.55). Vitamin D supplement use was also not associated 
with increased risk of early menopause (P-trend = 0.10). 
Results from analyses of calcium intake and early menopause are presented in 
Table 2.3. Age-adjusted and MV1 estimates for total, dietary, and dairy calcium intake 
were similar to those for vitamin D. For example, in MV1, dietary calcium intake in the 
highest quintile was associated with a borderline significant 13% lower risk of early 
menopause (95% CI: 0.76, 1.00; P-trend = 0.03) as compared to the lowest. High calcium 
intake from dairy sources was also associated with borderline significant lower risk (Q5 
vs. Q1 HR: 0.87, 95% CI: 0.75, 1.00; P-trend = 0.03), while non-dairy dietary calcium 
intake was not associated with risk of early menopause (Q5 vs. Q1 HR: 1.01, 95% CI: 
0.85, 1.20, P-trend = 0.99). Calcium supplement intake was positively associated with 
risk of early menopause (P-trend <0.01). 
In an attempt to disentangle the individual associations of vitamin D and calcium 
with risk of early menopause, we mutually adjusted corresponding sources of vitamin D 
and calcium in a second multivariable model. After adjustment, estimates were similar 
while confidence intervals were wider and no longer statistically significant (complete 
results not shown). For example, in this model, calcium intake from dairy foods in 
quintile 5 versus quintile 1 was associated with a non-significant 12% decreased risk of 
early menopause (HR: 0.88; 95% CI: 0.67, 1.14; P-trend = 0.29). The association for 
vitamin D intake from dairy foods was also attenuated (Q5 vs. Q1 HR: 0.96; 95% CI: 
0.74, 1.25; P-trend = 0.94) 
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 Results from MV1 logistic regression models assessing intakes of vitamin D and 
calcium from dietary and supplemental sources at ages 35 and 40 are presented in Table 
2.4. At age 35, intake of supplemental vitamin D ≥600 IU/d compared to non-supplement 
users was associated with higher risk (OR: 1.93; 95% CI: 1.15, 3.22), while calcium 
supplement use was not associated with risk of early menopause. Intakes of dietary 
vitamin D and calcium were both inversely associated with risk of early menopause. 
Similarly, at age 40, intakes of both dietary vitamin D and calcium were inversely 
associated with early menopause. Supplemental vitamin D intake was not associated with 
risk, whereas high intake of supplemental calcium was associated with increased risk 
(≥900 mg/d vs. non-users: OR: 1.60; 95% CI: 1.19, 2.17; P-trend = 0.02) 
 Results from analyses among never smokers were similar but slightly stronger in 
magnitude than in main analyses (data not shown). The likelihood ratio test comparing 
models with and without total vitamin D-BMI multiplicative interaction terms was not 
statistically significant (P-interaction = 0.22). BMI also did not modify the dietary 
vitamin D-early menopause relation (P-interaction = 0.41). Estimates from analyses 
excluding non-cases with menopause occurring before age 48, and analyses censoring at 
diagnosis of endometriosis and uterine fibroids were similar to estimates from main 
analyses (data not shown). Tests of proportional hazards were not statistically significant, 
indicating that the proportional hazards assumption was met. 
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2.5 Discussion 
In this prospective study, we found high intakes of vitamin D and calcium from 
food sources to be modestly associated with lower risk of early menopause. Contrarily, 
supplemental vitamin D was not associated with risk of early menopause and 
supplemental calcium was positively associated with early menopause.  
The inverse associations for vitamin D and calcium from food sources appear to 
be driven largely by dairy sources of these nutrients, and mutual adjustment of vitamin D 
for calcium and vice-versa attenuated findings for each. While we are aware of no prior 
studies that have assessed dairy vitamin D and calcium specifically, Carwile et al 
observed that low-fat dairy, but not high-fat dairy intake, was associated with a later age 
of menopause, among women <51 years of age. (8) A similar association was reported in 
an abstract from the Japan Nurses’ Health Study, which observed an inverse association 
of milk and dairy consumption on risk of early menopause; however, specific details 
about exposure and covariate measurement in this unpublished study are unavailable. 
(149) In contrast, dairy consumption was not associated with menopausal timing in a 
study within the European Prospective Investigation into Cancer and Nutrition. 
It is notable that Carwile et al, similarly did not find total vitamin D or calcium 
intake to be related to age at menopause. (8) Their study, however, did not separately 
evaluate dietary versus supplemental sources of these nutrients, which may have 
attenuated associations for vitamin D from foods. In our study, high doses of 
supplemental calcium were associated with higher risk of early menopause. The observed 
higher risk among supplement users was unexpected, and we postulate that these women 
may have experienced conditions related to sex steroid hormone levels prior to early 
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menopause for which their doctors indicated a calcium supplement, such as autoimmune 
diseases or family history of osteoporosis. 
To further address this potential bias, we also conducted a post hoc analysis (n for 
analysis = 1,757 cases) excluding women with conditions potentially related to both 
vitamin D and supplement use (e.g. lupus, multiple sclerosis, rheumatoid arthritis, low 
bone density, hip fracture, and osteoporosis). Estimates from these analyses were 
essentially identical to main analyses. We also considered the possibility that women 
were taking multivitamins containing supplemental vitamin D and calcium to treat 
perimenopause symptoms prior to early menopause. Nevertheless, after further 
controlling for multivitamin use, the positive association for supplemental calcium intake 
persisted.  
The observed inverse association of dairy calcium and the borderline significant 
inverse association of dairy vitamin D specifically suggest that other constituents of dairy 
products may also influence menopause timing. Bovine milk is a rich source of steroid 
hormones - particularly progesterone; for example, whole milk contains 10 µg of 
progesterone per liter. (67) Milk consumption has also been shown to increase levels of 
plasma estradiol (86) and insulin-like growth factor (IGF-I) (89,90,92) in prior 
epidemiologic studies. It is therefore biologically plausible that these components, which 
are highly correlated with intakes of vitamin D and calcium in dairy, also contribute to 
the inverse associations observed. Studies of dairy foods and dairy constituents, such as 
phosphorus, potassium, and vitamin B-12, and early menopause are thus warranted.  
Given that vitamin D and calcium are typically present together in specific foods, 
the attenuation of the estimates for each nutrient after mutual adjustment is likely due to 
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the collinearity of vitamin D and calcium. In our population, the Pearson correlation 
coefficient for dairy vitamin D and calcium in this population was 0.86 (P<0.001). It is 
likely that vitamin D and calcium each have individual contributions to the observed 
estimates, but separating out the associations for each nutrient is statistically impossible 
due to near perfect collinearity.  
The observed inverse association for dietary vitamin D also may be due to a 
modest protective effect of vitamin D and calcium on ovarian aging. Several potential 
mechanisms supporting this hypothesis have been proposed – namely, the ability of 
vitamin D to modify mRNA expression of anti-Müllerian hormone, a glycoprotein 
secreted by granulosa cells during early follicle development that correlates with overall 
age at menopause and may play a role in regulating ovarian aging. (25,27,77,115,166) 
Because the majority of vitamin D is obtained via cutaneous synthesis during solar 
ultraviolet ray exposure, dietary and supplemental intake of vitamin D represents a small 
overall contribution to circulating plasma 25-hydroxyvitamin D (25(OH)D). (167) To 
better understand how vitamin D status is related to early menopause, future biomarker 
studies of anti-Müllerian hormone, plasma 25(OH)D levels and menopause timing are 
warranted. 
Strengths of our study include a prospective design with 20 years of follow-up 
and a large sample size that allowed us to consider a variety of potential confounding 
variables. During this follow-up period, we were able to assess intakes of vitamin D and 
calcium five times and use cumulative averages of exposures, allowing us to capture 
within-person variation in diet and reduce misclassification. (164) Our study expanded 
upon prior studies by assessing early menopause specifically, rather than overall age at 
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menopause as an outcome. Menopausal timing follows a normal distribution, with a mean 
of 51 years of age. (6) In a prior study of other factors and menopausal timing, 
associations of nutrients varied across age strata (8), supporting the use of the binary 
early menopause outcome, rather than a continuous distribution of age at menopause with 
respect to evaluating risk factors.  
Our study also has several limitations. First, because biochemical confirmation of 
age at menopause was not feasible in a study of this size, we relied upon self-reported 
menopausal status to determine timing of menopause. However, in a study of 6,591 
women in the comparable NHS population, among women who were premenopausal in 
1976 and reported having natural menopause on the 1978 questionnaire, 82% reported 
their age at menopause to within 1 year on the following two questionnaires. (168) 
Importantly, any misclassification of early menopause would most likely be biased 
towards null. Moreover, in a sensitivity analysis restricting non-cases to women with 
menopause after age 48, we found estimates to be identical, suggesting that our results 
are robust to misclassification of the outcome. Furthermore, while we cannot rule out the 
possibility of systematic over- or under-reporting of total energy, alcohol, and nutrients 
including vitamin D, calcium and vegetable protein, it is unlikely that reporting patterns 
for dietary variables would be related to case status. Misclassification across extreme 
categories is improbable and would not explain the observed inverse associations for 
intakes dietary and dairy vitamin D and calcium.  
Because the NHS2 is a fairly heterogeneous population with regard to the dietary 
variables and other lifestyle factors related to early menopause, we anticipate that our 
results would be generalizable to other populations of premenopausal women. However, 
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given that the NHS2 is racially homogenous, our ability to assess differences in the 
vitamin D/calcium-early menopause relation across racial and ethnic groups is limited 
and our findings should be replicated in more racially diverse populations. It is also 
important to note that in the NHS2, dietary vitamin D intake in the highest category is 
higher than what has been reported in other population-based studies (169) and thus may 
not reflect typical intake in the U.S. Findings from our study suggest that vitamin D and 
calcium from food sources, particularly dairy, are modestly associated with lower risk of 
early menopause. Further studies examining risk of early menopause with regard to dairy 
constituents and plasma vitamin D levels are warranted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2.1 Age-adjusted characteristics of premenopausal women according to category of total vitamin D and 
calcium intake (intake from foods and supplements combined) at baseline (1991): Nurses’ Health Study II, 19911 		 Total Vitamin D (Quintiles) Total Calcium (Quintiles) 
Characteristic	 Q1 (n=17000) Q2 (n=17069) Q3 (n=17438) Q4 (n=17421) Q5 (n=17306) Q1 (n=17024) Q2 (n=17333) Q3 (n=17440) Q4 (n=17476) Q5 (n=16961) 
Calcium 
intake,2 mg/d 684 ± 2.7 842 ± 2.7 1024 ± 2.7 1156 ± 2.7 1364 ± 2.7 570 753 923 1163 1560 
           
Vitamin D 
intake,3 IU/d 128 217 317 473 742 214 ± 1.7 289 ± 1.7 370 ±1.7 459 ± 1.7 617 ± 1.7 
Age,4 y  36.1 ± 4.6 36.1 ± 4.6 35.9 ± 4.6 35.5 ± 4.6 35.3 ± 4.5 36.2 ± 4.6 35.9 ± 4.6 35.7 ± 4.6 35.5 ± 4.6 35.6 ± 4.7 
BMI, kg/m2 24.8 ± 0.04 24.6 ± 0.04 24.5 ± 0.04 24.4 ± 0.04 24.3 ± 0.04 24.6 ± 0.04 24.6 ± 0.04 24.6 ± 0.04 24.4 ± 0.04 24.4 ± 0.04 
Age at 
menarche, y 12.4 ± 0.01 12.4 ± 0.01 12.4 ± 0.01 12.4 ± 0.01 12.4 ± 0.01 12.4 ± 0.01 12.4 ± 0.01 12.4 ± 0.01 12.4 ± 0.01 12.4 ± 0.01 
           
Full-term 
pregnancies, n 1.6 ± 0.01 1.6 ± 0.01 1.6 ± 0.01 1.6 ± 0.01 1.5 ± 0.01 1.5 ± 0.01 1.6 ± 0.01 1.5 ± 0.01 1.6 ± 0.01 1.5 ± 0.01 
           
Physical 
activity,  
MET-h/wk 
20.6 ± 0.5 23.1 ± 0.50 24.9 ± 0.5 25.0 ± 0.5 27.5 ± 0.5 21.3 ± 0.5 23.2 ± 0.5 24.8 ± 0.5 24.9 ± 0.5 26.9 ± 0.5 
           
Vegetable 
protein intake, 
% of total kcal 
5.0 ± 0.01 5.1 ± 0.01 5.0 ± 0.01 5.0 ± 0.01 5.0 ± 0.01 4.8 ± 0.01 5.1 ± 0.01 5.2 ± 0.01 5.0 ± 0.01 4.9 ± 0.01 
           
Alcohol intake, 
g/d 3.5 ± 0.05 3.3 ± 0.05 3.2 ± 0.05 3.1 ± 0.05 2.5 ± 0.05 3.5 ± 0.05 3.6 ± 0.05 3.3 ± 0.05 2.9 ± 0.05 2.5 ± 0.05 
           
Ever used OCs, 
% 84.8 84.7 84.3 82.9 83.4 84.2 84.6 84.0 83.4 83.8 
Current smoker, 
% 16.4 12.9 10.9 10.0 9.1 17.1 12.9 10.9 9.7 8.7 
1Values are means ± SEs or percentages, unless otherwise indicated. All characteristics were calculated with the use of generalized linear models adjusted for the 
age of participants in 1991. MET-h, metabolic equivalent task hours; Q, quintile. 
2Values reflect total calcium intake (mg/d) per quintile of total vitamin D and quintile medians for total calcium. 
3Values reflect total vitamin D intake (IU/d) per quintile of total calcium and quintile medians for total vitamin D. 
4Values are not age-adjusted. Values are means ± SDs. 
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Table 2.2 HRs (95% CIs) for early menopause by level of cumulatively 
averaged vitamin D intake: Nurses’ Health Study II (1991-2011)1 
  Median Cases 
Age-adjusted 
HR (95% CI) 
Multivariable 12 HR 
(95% CI) 
Total Vitamin D (IU/d) 	 	 	
Q1 145 438 1 1 
Q2 241 392 0.86 (0.75, 0.99) 0.89 (0.78, 1.02) 
Q3 341 419 0.90 (0.79, 1.03) 0.95 (0.83, 1.08) 
Q4 474 399 0.89 (0.77, 1.02) 0.94 (0.82, 1.07) 
Q5 695 393 0.95 (0.83, 1.09) 0.99 (0.86, 1.13) 
P-trend 	 	 0.80 0.76 
RDA (IU/d) 	 	 	 	
<600 301 1711 1 1 
≥600 721 330 1.02 (0.90, 1.15) 1.02 (0.91, 1.15) 
Dietary Vitamin D 	 	 	 	
Q1 148 441 1 1 
Q2 232 424 0.94 (0.82, 1.07) 0.97 (0.85, 1.11) 
Q3 301 375 0.81 (0.71, 0.93) 0.85 (0.74, 0.98) 
Q4 383 441 0.96 (0.84, 1.09) 1.01 (0.88, 1.15) 
Q5 528 360 0.79 (0.69, 0.91) 0.83 (0.72, 0.95) 
P-trend 	 	 <0.01 0.03 
Vitamin D from Dairy 
Sources 	 	 	 	
Q1 25 436 1 1 
Q2 62 403 0.88 (0.77, 1.01) 0.90 (0.79, 1.03) 
Q3 101 399 0.86 (0.75, 0.99) 0.90 (0.78, 1.03) 
Q4 153 419 0.88 (0.77, 1.01) 0.92 (0.80, 1.05) 
Q5 254 384 0.82 (0.71, 0.94) 0.85 (0.74, 0.98) 
P-trend 	 	 0.02 0.06 
Non-Dairy Dietary 
Vitamin D 	 	   
Q1 46 436 1 1 
Q2 75 421 0.96 (0.84, 1.10) 1.02 (0.89, 1.16) 
Q3 101 401 0.93 (0.81, 1.07) 0.99 (0.86, 1.14) 
Q4 135 397 0.93 (0.81, 1.06) 0.98 (0.86, 1.13) 
Q5 196 386 0.94 (0.81, 1.07) 0.97 (0.84, 1.12) 
P-trend   0.32 0.55 
Supplemental Vitamin D 
(IU/d) 	 	 	 	
0 0 899 1 1 
1-599 209 1102 1.01 (0.92, 1.11) 1.04 (0.95, 1.15) 
≥600 800 40 1.30 (0.94, 1.78) 1.29 (0.94, 1.77) 
P-trend 		 		 0.23 0.10 
1MET, metabolic equivalent task; Q, quintile; RDA, Recommended Daily Allowance. 
2Multivariable Cox proportional hazards model adjusted for age, pack-years of smoking (0-10, 
11-20, or ≥21), BMI [in kg/m2 (<18.5, 18.5-<25, 25-<30, or ≥30)], age at menarche (continuous), 
parity (nulliparous, 1-2, or ≥3), breastfeeding duration (in months; continuous), physical activity (in 
continuous MET-h/wk), % of total calories from vegetable protein (quintiles 1-3, 4+5), and alcohol 
intake (<10, ≥10 g/d).                                                                                                                                                                        
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Table 2.3 HRs (95% CIs) for early menopause by level of cumulatively averaged 
calcium intake: Nurses’ Health Study II (1991-2011)1 
  Median Cases 
Age-adjusted 
HR (95% CI) 
Multivariable 12 
HR (95% CI) 
Total Calcium (mg/d) 	 	 	
Q1 609 419 1 1 
Q2 802 477 1.09 (0.95, 1.24) 1.16 (1.01, 1.32) 
Q3 982 421 0.96 (0.84, 1.10) 1.04 (0.90, 1.19) 
Q4 1205 337 0.79 (0.68, 0.91) 0.86 (0.74, 0.99) 
Q5 1566 387 1.01 (0.88, 1.15) 1.09 (0.94, 1.25) 
P-trend 	 	 0.11 0.60 
RDA (mg/d) 	 	 	 	
<1,000 771 1177 1 1 
≥1,000 1270 864  0.89 (0.82, 0.97) 0.93 (0.85, 1.01) 
Dietary Calcium 	 	 	 	
Q1 556 426 1 1 
Q2 705 414 0.91 (0.79, 1.04) 0.96 (0.84, 1.10) 
Q3 832 437 0.95 (0.83, 1.09) 1.02 (0.89, 1.17) 
Q4 987 390 0.83 (0.73, 0.96) 0.90 (0.78, 1.03) 
Q5 1246 374 0.81 (0.70, 0.93) 0.87 (0.76, 1.00) 
P-trend 	 	 <0.01 0.03 
Calcium from Dairy Sources 	 	 	 	
Q1 246 426 1 1 
Q2 382 410 0.90 (0.79, 1.03) 0.94 (0.82, 1.08) 
Q3 503 426 0.93 (0.81, 1.06) 0.97 (0.85, 1.11) 
Q4 657 397 0.85 (0.74, 0.97) 0.90 (0.78, 1.03) 
Q5 926 382 0.83 (0.72, 0.95) 0.87 (0.75, 1.00) 
P-trend 	 	 <0.01 0.03 
Non-Dairy Dietary Calcium 	 	   
Q1 235 415 1 1 
Q2 280 430 1.02 (0.89, 1.17) 1.11 (0.96, 1.27) 
Q3 312 398 0.92 (0.80, 1.06) 1.03 (0.89, 1.20) 
Q4 347 421 0.98 (0.85, 1.12) 1.12 (0.96, 1.31) 
Q5 410 377 0.89 (0.77, 1.02) 1.01 (0.85, 1.20) 
P-trend 	 	 0.06 0.99 
Supplemental Calcium (mg/d) 	 	 	 	
0 0 1019 1 1 
1-399 139 714 0.98 (0.88, 1.08) 1.01 (0.91, 1.12) 
400-899 512 252 1.31 (1.14, 1.50) 1.36 (1.18, 1.56) 
≥900 1015 56 0.99 (0.75, 1.29) 1.03 (0.78, 1.35) 
P-trend   0.02 <0.01 
Vitamin D or Calcium 
Supplement Use     
Non-user 772 N/A 1 1 
Vitamin D only 247 N/A 0.99 (0.86, 1.14) 1.01 (0.87, 1.17) 
Calcium only 127 N/A 1.06 (0.88, 1.28) 1.09 (0.90, 1.32) 
Calcium + Vitamin D 895 N/A 1.04 (0.94, 1.16) 1.09 (0.98, 1.21) 
1MET, metabolic equivalent task; Q, quintile; RDA, Recommended Daily Allowance.  
2Multivariable Cox proportional hazards model adjusted for age, pack-years of smoking (0-10, 11-
20, or ≥21), BMI [in kg/m2 (<18.5, 18.5-<25, 25-<30, or ≥30)], age at menarche (continuous), parity 
(nulliparous, 1-2, or ≥3), breastfeeding duration (in months; continuous), physical activity (in 
continuous MET-h/wk), % of total calories from vegetable protein (quintiles 1-3, 4+5), and alcohol 
intake (<10, ≥10 g/d).                                                                                                                                                                        
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Table 2.4 Multivariable ORs (95% CIs) for early menopause vitamin D and 
calcium intakes assessed at ages 35 and 40: Nurses’ Health Study II (1991-2011)1-3 		 	Intake Assessed at Age 35 	 	Intake Assessed at Age 40 	 Median Cases OR (95% CI)  Median Cases OR (95% CI) 
Dietary Vitamin D 	 	 	 	 	 	 	
Q1 107 114 1  76 119 1 
Q2 170 122 1.04 (0.80, 1.35)  137 96 0.76 (0.58, 1.00) 
Q3 226 89 0.71 (0.54, 0.95)  190 107 0.89 (0.68, 1.17) 
Q4 295 103 0.81 (0.62, 1.07)  254 108 0.86 (0.66, 1.13) 
Q5 403 106 0.80 (0.61, 1.05)  363 104 0.82 (0.63, 1.08) 
P-trend 	 	 0.04 	 	 	 0.38 
Supplemental 
Vitamin D (IU/d) 
	 	 	 	 	 	 	
0 0 306 1  0 258 1 
1-599 400 211 0.81 (0.68, 0.98)  228 266 1.10 (0.92, 1.31) 
≥600 800 17 1.93 (1.15, 3.22)  800 10 0.89 (0.47, 1.70) 
P-trend 	 	 0.33 	 	 	 0.67 
Dietary Calcium 	 	 	 	 	 	 	
Q1 527 106 1  509 104 1 
Q2 680 93 0.77 (0.57, 1.02)  661 109 1.07 (0.81, 1.43) 
Q3 814 113 0.87 (0.66, 1.14)  797 117 1.08 (0.82, 1.42) 
Q4 988 108 0.76 (0.58, 1.01)  973 102 0.90 (0.68, 1.19) 
Q5 1284 114 0.77 (0.59, 1.01)  1280 102 0.89 (0.67, 1.18) 
P-trend 	 	 0.12 	 	 	 0.17 
Supplemental 
Calcium (mg/d) 
	 	 	 	 	 	 	
0 0 353 1  0 286 1 
1-399 162 117 0.89 (0.72, 1.10)  162 131 1.08 (0.88, 1.34) 
400-899 500 44 1.07 (0.77, 1.48)  500 62 0.93 (0.70, 1.23) 
≥900 1055 20 1.15 (0.72, 1.82)  1000 55 1.60 (1.19, 2.17) 
P-trend 	 	 0.59 	 	 	 0.02 
Vitamin D or 
Calcium 
Supplement 
 
  
  
  
Non-user N/A 282 1  N/A 225 1 
User N/A 252 0.88 (0.74, 1.05)  N/A 309 1.08 (0.90, 1.29) 
1MET, metabolic equivalent task; Q, quintile. 
2Analysis limited to women with vitamin D and calcium intake assessed at both age 35 and age 40; 
case ascertainment limited to women with early menopause occurring after diet assessment at age 40. 
3 Multivariable Cox proportional hazards model adjusted for age, pack-years of smoking (0-10, 11-
20, or ≥21), BMI [in kg/m2 (<18.5, 18.5-<25, 25-<30, or ≥30)], age at menarche (continuous), parity 
(nulliparous, 1-2, or ≥3), breastfeeding duration (in months; continuous), physical activity (in continuous 
MET-h/wk), % of total calories from vegetable protein (quintiles 1-3, 4+5), and alcohol intake (<10, ≥10 
g/d).                                                                                                                                                                        
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CHAPTER 3 
TOTAL AND FREE 25-HYDROXYVITAMIN D AND VITAMIN D BINDING 
PROTEIN LEVELS AND RISK OF EARLY MENOPAUSE 
3.1 Abstract 
Early natural menopause, the cessation of ovarian function before age 45 y, is associated 
with higher risk of cardiovascular disease and other conditions. Dietary vitamin D intake 
has been associated with lower risk of early menopause; however, no prior studies have 
evaluated risk with regard to plasma 25-hydroxyvitamin D (25(OH)D) levels. We 
prospectively evaluated the association of total and free 25(OH)D and vitamin D binding 
protein (VDBP) levels with risk of early menopause in a case-control study nested within 
the Nurses’ Health Study II (NHS2). We also considered associations of 25(OH)D and 
VDBP with levels of anti-Müllerian hormone (AMH). The NHS2 is a prospective cohort 
study of 116,430 nurses, aged 25-42 y at baseline (1989). Premenopausal plasma blood 
samples were collected between 1996-1999, from which total 25(OH)D and VDBP levels 
were measured and free 25(OH)D levels were calculated. Cases were women who 
experienced natural menopause between blood collection and age 45 y (n=328) and were 
matched 1:1 to controls experiencing menopause after age 48 y (n=328) by age and other 
factors. In multivariable conditional logistic models adjusting for matching factors, 
smoking, body mass index, and other factors, total and free 25(OH)D were not strongly 
associated with risk of early menopause. Odds ratios (OR) comparing the highest vs. 
lowest quartile was 1.04 (95% CI: 0.60, 1.81) for total 25(OH)D and 0.70 (95% CI: 0.41, 
1.20) for free 25(OH)D. Plasma 25(OH)D was unrelated to AMH levels. VDBP was 
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positively associated with early menopause; the OR comparing the highest vs. lowest 
quartile of VDBP was 1.80 (95% CI: 1.09, 2.98). Our findings suggest that total and free 
25(OH)D are not importantly related to risk of early menopause. VDBP may be 
associated with increased risk, but replication in more racially-diverse populations is 
warranted.  
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3.2 Introduction 
 Early menopause, which is the cessation of ovarian function before the age of 45 
y, affects approximately 10% of women in Western populations. (1) Women who 
experience early menopause are at increased risk for premature mortality and cognitive 
decline, osteoporosis, and cardiovascular disease, as well as other adverse health 
outcomes. (2–5) Early menopause may also be problematic for couples trying to 
conceive, as female fertility declines drastically during the 10 years leading up to 
menopause. Couples unable to conceive as they wish may experience substantial 
financial and psychological consequences, particularly as women increasingly delay 
childbearing into the later reproductive years. (1,6) As such, it is important to identify 
modifiable lifestyle factors that may be related to early menopause risk, including diet.  
Accelerated ovarian aging, the mechanism thought to underlie early menopause, 
is characterized by a decline in the quantity and quality of the ovarian follicle pool. (6) 
During the reproductive years, primordial follicle growth and transition to primary 
follicles are inhibited by anti-Müllerian hormone (AMH), a glycoprotein secreted by the 
granulosa cells of primary, secondary, and small antral follicles. Notably, a vitamin D 
response element has been identified in the promoter region of the AMH gene (75), 
suggesting a potential role of vitamin D in AMH secretion and thus follicle recruitment. 
In line with this hypothesis, laboratory studies have demonstrated that vitamin D 
upregulates AMH mRNA expression in both human prostate cells and granulosa cells of 
hen. (76,77) 
Findings of a recent study in the Nurses’ Health Study II (NHS2) cohort suggest 
that vitamin D intake from food sources, particularly dairy sources, is associated with 
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lower risk of early menopause. (60) Because vitamin D is obtained through dietary intake 
as well as sunlight exposure, levels of 25(OH)D, the primary circulating metabolite of 
vitamin D, is a better indicator of vitamin D status than dietary intake alone. To our 
knowledge, no prior studies have evaluated 25(OH)D levels and risk of early menopause 
and findings of epidemiologic studies evaluating 25(OH)D levels and AMH are 
conflicting. (115,166,170,171) One recent study found that AMH levels exhibit seasonal 
variation correlated with 25(OH)D levels and that vitamin D supplementation prevented a 
seasonal decline in AMH levels. (166) An additional study among U.S. women found 
25(OH)D to be positively associated with AMH levels (115), while three more recent 
studies reported no association. (170,171) 
It is also currently unclear whether measures of total versus free 25(OH)D levels 
may have different relationships with ovarian aging. At any given time, over 99% of 
vitamin D in the body is bound to vitamin D binding protein or albumin, leaving less than 
1% unbound. (73) Because vitamin D binding protein levels influence the bioavailability 
of vitamin D, assessing total versus free 25(OH)D levels, as well as levels of vitamin D 
binding protein may be important for understanding the potential relation of vitamin D 
and early menopause. In fact, recent epidemiologic studies have observed that the free 
25(OH)D fraction, as compared to total 25(OH)D, is more strongly associated with 
several health outcomes such as bone mineral density (172) and colorectal cancer. (173)  
The aims of the present nested case-control study were thus to evaluate 
associations of total 25(OH)D, free 25(OH)D, and vitamin D binding protein levels 
(VDBP) and risk of early menopause among participants of the NHS2. 
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3.3 Subjects and Methods 
The NHS2 is a prospective study of 116,429 female U.S. registered nurses who 
were 25-42 years old in 1989 when they responded to a mailed baseline questionnaire. 
Information regarding lifestyle behaviors and medical conditions are collected through 
biennial questionnaires, for which the follow-up rate for each cycle has been at least 89%. 
The study protocol was approved by the institutional review board at Brigham and 
Women’s Hospital in Boston, MA.  
3.3.1 Case and control ascertainment 
On the 1989 baseline questionnaire, nurses were asked if their menstrual periods 
had ceased permanently and were provided the following response options: 1) No: 
Premenopausal; 2) Yes: No menstrual periods; 3) Yes: had menopause but now have 
periods induced by hormones; and 4) Not sure; (e.g., started hormones prior to cessation 
of periods). Nurses who indicated that their periods had ceased were then asked the 
following questions: 1) At what age did your periods cease? (open response); and 2) For 
what reason did your periods cease? (response options were surgery; radiation or 
chemotherapy; and natural). Women were also asked about their current and past use of 
menopausal hormone therapy (HT). Questions regarding menopausal status and use of 
HT were then repeated on all subsequent questionnaires. 
A small number of women reported being postmenopausal on one questionnaire 
after a long interval of amenorrhea, only to have periods return again and report being 
premenopausal on a subsequent questionnaire. For these women, we defined age at 
menopause as age after which periods were absent for 12 mo or more, and then 
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confirmed that this status persisted for at least 3 consecutive questionnaires in order to 
reduce potential for misclassification of early menopause.  
3.3.2 Blood sample collection 
Participants of the NHS2 who had not previously been diagnosed with cancer 
(n=92,888) were invited to provide blood samples between 1996 and 1999. During this 
time period, participants were ages 32-54 y. Premenopausal women who were not 
pregnant and were not using oral contraceptives (OC) or menopausal HT, were asked to 
provide two samples during the span of one menstrual cycle. The first sample was to be 
collected during the follicular phase (days 3-5 of the menstrual cycle) and the second was 
to be collected during the luteal phase (7-9 days before the start of the next menses). 
Women who were using OCs or menopausal HT were asked to provide a single untimed 
sample, and women who reported irregular menstrual cycles were asked to collect a luteal 
phase sample 22 days after the last menses. To confirm timing and menstrual cycle phase 
of the samples, women completed a postcard at the start of their next menses. Upon 
receipt, blood samples were centrifuged, separated into plasma, buffy, and red blood cell 
components and then stored at ≤-130 °C in nitrogen freezers.  
Among eligible women, 29,611 provided a sample and ~23,000 of these women 
were premenopausal at the time of blood draw. Women who provided samples were 
similar to the entire NHS2 cohort, having equivalent BMI (26 vs. 26 kg/m2) and parity 
(1.9 vs. 1.9 children), and comparable proportions of ever smoking (34% vs. 36%) and 
history of OC use (86% vs. 88%), as well as other factors. (174) 
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Because we were interested in prospectively evaluating the relation of plasma 
25(OH)D levels and risk of early menopause, we limited eligibility to women who 
experienced menopause after blood draw. In addition, our study sample was limited to 
women without a previous diagnosis of cancer (other than non-melanoma skin cancer), 
myocardial infarction, stroke, coronary artery bypass surgery, or percutaneous coronary 
intervention and women who had available plasma samples. Cases of early menopause 
were then defined as women reporting natural menopause (i.e., not due to surgery or 
chemotherapy) before the age of 45 y during follow-up. To reduce potential for 
misclassification of early menopause status, eligible controls were women who 
experienced menopause after age 48 y (Q3 of the interquartile range (IQR)).  
Eligible cases (n=328) were then matched 1:1 to controls according to age at 
blood collection (within 4 mo), time of day of blood collection, month of collection 
(within 3 mo), sample type (luteal phase or untimed) and fasting status.  
3.3.3 Laboratory assays 
Plasma 25(OH)D, VDBP, albumin, and AMH were measured in the laboratory of 
Dr. Nader Rifai at Boston’s Children’s Hospital (Boston, MA). Immunoassays were used 
for measurement of plasma 25(OH)D (Immunodiagnostic Systems Inc., Fountain Hills, 
AZ) and plasma VDBP (R&D Systems (Minneapolis, MN)). The immunoassay used to 
measure plasma VDBP was a monoclonal antibody. Plasma AMH was measured using 
the pico AMH assay from ANSH Labs (Webster, TX). 
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Using measured values of plasma total 25(OH)D, VDBP, and albumin for each 
individual, we calculated each participants’ plasma free 25(OH)D level according to the 
following equation (175): 
!"##	25 '( )	(+,-. /) = 2-23.	25 '( )	(4,-. /)1 + 6×10:×	3.;<,=4	(> /) + (7×10@×A)BC	(D,-. /)) 
To prevent potential exposure measurement error related to case status, laboratory 
personnel were blinded to case/control status for all assays. Samples were labeled by 
number and matched case-control sets were handled together, shipped in the same batch, 
and assayed in the same analytical run. Masked quality control samples were randomly 
interspersed among case-control samples and were analyzed in each batch. The 
coefficients of variation for biomarkers were 4.9% for total 25(OH)D, 7.2% for VDBP, 
and 8.6% for AMH.   
3.3.4 Assessment of covariates 
Variables used as matching factors, including age at blood collection, time of day 
of blood collection, month of collection, sample type (luteal phase or untimed), and 
fasting status were assessed at the time of blood draw. We also considered the following 
variables for inclusion in multivariable models based on previous studies of risk factors 
for early menopause: race/ethnicity, smoking, BMI, parity, physical activity, OC use and 
duration, duration of breastfeeding, alcohol intake, and vegetable protein intake. Height 
and race/ethnicity were assessed at baseline in 1989 and information regarding smoking 
status, weight (to calculate BMI), alcohol intake, fasting status, and menstrual cycle 
phase were collected at the time of blood draw by separate questionnaire. Updated 
information regarding smoking, weight, OC use, parity, and breastfeeding was assessed 
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on biennial questionnaires beginning in 1989. Physical activity was assessed in 1989, 
1991, 1997, 2001, and 2005 using validated questionnaires. (163) Finally, validated food 
frequency questionnaires (FFQ) administered every 4 years were used to assess dietary 
intake of total calories, alcohol, and vegetable protein. (159–161) Intakes of nutrients 
were adjusted for total energy using the residual method. (162) For time-varying 
covariates, we modeled variables that corresponded to questionnaires closest in time to 
blood collection for each individual.   
3.3.5 Statistical analysis 
We used Chi-square and t-tests to compare characteristics of early menopause 
cases and controls at the time of blood draw and histogram and normality plots to assess 
the normality of biomarker data. Participants were divided into quartiles of total 
25(OH)D, free 25(OH)D, and VDBP based on the distribution of these biomarkers in the 
control group. Likelihood ratio tests comparing nested models to were used to assess the 
global significance of each biomarker. We also categorized participants according to the 
following cutpoints: <50, 50-<75, and ≥75 nmol/L. (176) For analyses using continuous 
biomarker data, we identified and removed outliers using the Rosner extreme studentized 
deviate test and standardized continuous variables to aid in interpretability. Relations of 
total and free 25(OH)D with log(AMH) were evaluated using multivariable generalized 
linear models. We then back-calculated AMH geometric means and 95% confidence 
intervals (CI) according to each quartile of total and free 25(OH)D.  
For each exposure, we used conditional logistic regression to calculate odds ratios 
(OR) and 95% CI adjusting for matching factors only. We then controlled for potential 
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confounders of the 25(OH)D-early menopause relation using multivariable conditional 
logistic regression. Because none of the covariates that were tested produced a change in 
exposure estimates >10%, covariates in multivariable models were selected if they were 
importantly associated with the outcome in our population. 
To assess potential non-linear associations of each biomarker exposure with risk 
of early menopause, we additionally ran restricted cubic spline models. For these models, 
we specified four knots in order to evaluate the individual spline term contributions to the 
model fit and overall test for non-linearity. 
We also conducted a number of stratified analyses to assess potential effect 
modification of relations of vitamin D with incident early menopause. To assess potential 
variation in associations according to age, we stratified our analyses by median age at 
blood draw (40 yrs). Second, because vitamin D is sequestered in adipose tissue (165), 
we assessed potential BMI effect modification by stratifying according to 2 categories of 
BMI (<25 vs. ≥25 kg/m2). Third, to evaluate potential seasonal variation in the 25(OH)D-
early menopause relation, we stratified our analyses by season of blood collection 
(winter/spring and summer/fall).  
We also conducted sensitivity analyses to determine the robustness of estimates in 
primary analyses. Autoimmune conditions such as multiple sclerosis, rheumatoid 
arthritis, and lupus may be associated with lower 25(OH)D levels and earlier age at 
menopause. Accordingly, we conducted analyses excluding individuals diagnosed with 
these conditions at any point during follow-up. Similarly, we conducted analyses limited 
to women with luteal phase samples in order to address the potential impact of variation 
of biomarker measures due to menstrual cycle variability. We also conducted analyses 
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limited to never smokers to evaluate potential residual confounding due to 
misclassification of smoking amount among smokers. All analyses were conducted using 
SAS v9.4 software (SAS Institute Inc., Cary, NC). We used two-sided statistical tests 
performed at the 0.05 significance level for all analyses.  
3.4 Results 
Characteristics of cases and controls at the time of blood collection are presented 
in Table 3.1. At the time of blood collection, cases were more likely to identify as non-
White and to smoke, and reported lower intakes of alcohol, supplemental calcium, and 
total vitamin D and calcium than controls.  
In unadjusted analyses and analyses adjusting for important covariates, total 
25(OH)D levels were not associated with risk (Table 3.2). For example, the OR 
comparing the first and fourth quartile of total 25(OH)D was 1.04 (95% CI: 0.60-1.81) in 
our MV1 model. Results for free 25(OH)D were suggestive of a lower risk at the highest 
levels, but confidence intervals were wide and results were not significant (Q4 vs. Q1 
OR: 0.70; 95% CI: 0.41-1.20). High vitamin D binding protein was associated with 
increased risk, and results were stronger after adjustment for variables in MV1, with 
some evidence of a threshold of higher risk for quartiles 3 and 4 versus quartile 1 (Q3 vs. 
Q1 OR: 1.80; 95% CI: 1.10-2.95 and Q4 vs. Q1 OR: 1.80; 95% CI: 1.09-2.98). Results 
comparing women with total 25(OH)D levels of ≥75 versus those with <50 nmol/L were 
null (MV2 OR: 1.19; 95% CI: 0.57-2.46) (Table 3.4). For each exposure, results from 
restricted cubic spline models indicated no associations with early menopause – either 
linear or non-linear (P for all exposures > 0.10; complete results not shown).  
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We did not find that adjusted geometric means of AMH levels varied according to 
quartile of total (P=0.55) or free 25(OH)D levels (P=0.32) (Table 3.3). AMH geometric 
mean levels varied significantly across VDBP quartiles, with the lowest levels in Q3 and 
Q4 (P=0.04).  
Findings of the primary analyses were largely unchanged in models evaluating 
effect modification and in sensitivity analyses. Estimates from analyses of total 25(OH)D 
stratified by median age at blood draw (< or ≥40 yrs) were consistent with findings from 
main analyses (data not shown). Estimates for total 25(OH)D stratified by BMI 
(underweight/normal and overweight/obese) were unstable due to small numbers (data 
not shown). Season (summer/fall vs. winter/spring) did not modify associations for total 
25(OH)D or free 25(OH)D (P-interactions = 0.31 and 0.85, respectively). Estimates were 
also similar after restricting analyses to non-smokers (n=222 cases and 216 controls), 
women who provided timed blood samples (n=254 cases and 254 controls), and women 
without diagnoses of autoimmune conditions (n=321 cases and 319 controls). We also 
ran models using only ‘super-normal controls’ defined as women who experienced 
menopause at the population mean age of 51 years (n=328 cases and 63 controls). 
Estimates from these models were not materially different than those of our main 
analyses. For example, the MV1 OR for each 1 standard deviation increase in total 
25(OH)D was 1.29 (95% CI: 0.87-1.91) and for free 25(OH)D was 1.00 (95% CI: 0.68-
1.46).  
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3.5 Discussion 
 In this prospective study, we did not find vitamin D metabolite levels to be 
consistently or strongly associated with risk of early menopause, or with levels of plasma 
AMH, a marker of ovarian aging. Conversely, high versus low VDBP levels was 
associated with increased risk of early menopause and lower AMH levels.  
 To our knowledge, this is the first study to investigate the association of total and 
free 25(OH)D and vitamin D binding protein levels and risk of early menopause. A 
recent study of NHS2 participants by our research group observed a significant 17% 
lower risk of early menopause among women who consumed the highest vitamin D from 
food sources (Q5 median = 528 IU/d), as compared to those who consumed the least (Q1 
median = 148 IU/d). (60) In contrast, we observed that total vitamin D intake was not 
associated with risk, whereas supplemental vitamin D intake (≥600 versus 0 IU/d) was 
associated with increased risk. The lack of strong and consistent associations of 25(OH)D 
with risk in the present analysis suggests that other dietary components or lifestyle factors 
correlated with vitamin D in foods may be associated with early menopause, rather than 
vitamin D itself. In our previous study, we noted a stronger association for dairy sources 
of vitamin D compared with non-dairy dietary vitamin D. Other constituents of dairy, 
such as lactose, calcium, or progesterone, which are highly correlated with vitamin D in 
dairy, may have influenced the observed inverse association for dietary vitamin D. The 
potential importance of dairy foods generally, rather than vitamin D specifically, is also 
supported by findings of Carwile et al, who observed that low-fat dairy intake was 
associated with later age at menopause, among women younger than 51 years of age. (8) 
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To answer this question, future studies of dairy foods and dairy constituents and risk of 
early menopause are warranted.   
Vitamin D has been hypothesized to be related to ovarian aging and menopause 
timing primarily through effects on AMH and follicular development. Our null findings 
for 25(OH)D and AMH are consistent with those of three cross-sectional studies. (170, 
171, 177) Pearce et al observed no association of 25(OH)D and AMH among 340 
infertility treatment-seeking women <40 years of age living in South Australia. (170) 
Similarly, Drakopoulos et al also observed no association of 25(OH)D levels and AMH 
among an infertile population of 283 Belgian women <42 years of age, and Kim et al 
observed no association of 25(OH)D and AMH levels in 291 Korean women 35-49 years 
of age. (171, 177) 
In contrast, two other studies reported significant associations between 25(OH)D 
and AMH. In a clinical trial among 33 premenopausal women living in New Zealand, 
Dennis et al observed seasonal variation of AMH levels mirroring that of 25(OH)D in 
both direction and magnitude, as well as a stabilizing effect of vitamin D3 
supplementation on the seasonality of AMH levels. (166) This is in contrast to placebo 
and vitamin D2 supplementation groups, who experienced a statistically significant 
decline in AMH levels from summer to winter months. In another small trial, Naderi et al 
reported a statistically significant increase in both 25(OH)D levels and AMH levels after 
3 months of vitamin D supplementation among 30 infertile Iranian women with vitamin 
D insufficiency or deficiency. (178) Likewise, in a cross-sectional study of US women, 
Mehri et al observed a statistically significant 1.1% higher log-transformed AMH for 
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each 1 ng/mL higher 25(OH)D level among 388 women at least 40 years of age, but no 
association among younger women. (115) 
The inconsistency in findings between studies of 25(OH)D and AMH may 
potentially be explained by two important factors. First, it is possible that 25(OH)D may 
only be associated with changes in AMH levels among vitamin D deficient women. Both 
the Kim et al trial and the Merhi et al study were conducted among predominantly 
vitamin D deficient women. The Dennis et al trial did not provide baseline 25(OH)D 
levels of participants, but given the high latitude of residence of the study population, 
these women may have been vitamin D deficient prior to receiving the supplement or 
placebo, and thus supplementation may have been beneficial in preventing a seasonal 
decline in 25(OH)D and AMH levels. If a 25(OH)D-AMH association is only observable 
at the low end of the vitamin D spectrum, then one would expect to see an association 
only in populations with high prevalence of vitamin D deficiency, which the NHS2 is not. 
Given the small numbers of women with 25(OH)D levels below 35 nmol/L (n=28) in the 
NHS2, we were unable to address this possibility in our analyses.  
It is also possible that the 25(OH)D-AMH relation may vary across racial groups 
due to differences in VDBP, as VDBP concentrations and binding affinity are determined 
almost entirely by genetic polymorphisms specific to race and ethnicity. (179) The 
binding affinity and concentration of VDBP is directly related to the bioavailability of 
25(OH)D within the body, and thus may be biologically relevant to the mechanisms 
involved in ovarian aging. In our study, we observed a threshold of higher risk for early 
menopause among individuals in quartiles 2 through 4 of VDBP versus quartile 1, and a 
non-linear relation of VDBP with AMH levels, suggesting that VDBP levels and/or their 
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genetic determinants may be associated with risk. The NHS2, as well as the study 
populations of Pearce et al and Drakopolous et al. were almost entirely White, while that 
of Mehri et al was predominantly Black and Hispanic. If 25(OH)D is only associated 
with AMH in specific racial/ethnic groups, demographic differences in study populations, 
and thus the underlying population heterogeneity of VDBP polymorphisms, may provide 
some explanation for inconsistent findings.  
Our ability to evaluate associations of early menopause and AMH with free 
25(OH)D and VDBP in non-White individuals was limited for two reasons. First, given 
the racial homogeneity of the NHS2, we used a monoclonal rather than a polyclonal 
assay to measure VDBP, which has been shown to underestimate free 25(OH)D levels in 
non-White individuals. (180) Second, the NHS2 is comprised of mostly White women, 
and thus numbers of non-White individuals were too small to conduct race-stratified 
analyses. In light of evidence that the 25(OH)D-AMH relation may vary by race 
potentially due to VDBP differences, additional evaluation of 25(OH)D, VDBP and 
AMH in large, diverse populations is necessary. 
It is important to note additional limitations of our study. First, we relied upon 
single measurements of 25(OH)D, VDBP, and AMH. Because 25(OH)D levels are 
influenced heavily by recent sun exposure and dietary intake, it is possible that within-
person variability of 25(OH)D levels may have contributed measurement error, resulting 
in non-differential misclassification. However, in the NHS, a similar population of female 
health professionals, the intra-class correlation coefficients (ICC) for plasma 25(OH)D 
measured 2-3 years apart was 0.72 (P<0.001) (181), and for measurements 10 years apart 
was 0.51 (95% CI=0.42-0.60). (182) In a comparable population, the ICC for VDBP 
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measured over 1-3 years was 0.96 (P<0.001) (183), indicating that these biomarkers are 
relatively stable over time. Furthermore, while some researchers have raised questions 
about potential misclassification of vitamin deficiency status when 25OHD levels are 
measured by immunoassay, this technique is widely used and well validated for studies 
comparing disease risk across relative 25OHD levels, such as our study. (184) These 
factors help minimize the possibility that measurement error in biomarker data would 
explain our null findings for total and free 25(OH)D.   
 Second, we relied upon self-report of age at menopause, defined as the age at 
which periods were absent for 12 months, to ascertain cases and controls. Because 
women may experience amenorrhea and then have periods return again during 
perimenopause, some degree of measurement error in self-reported age at menopause is 
to be expected. Such measurement error would result in misclassification of early 
menopause cases and controls and produce a bias towards the null. However, among 
6,591 women in the comparable NHS population, 82% of women reported the same age 
at menopause over multiple questionnaire cycles, suggesting high reproducibility. (168) 
Furthermore, we restricted the control group to women with age at menopause >48 years 
to reduce potential misclassification of the outcome. As such, misclassification of cases 
and controls would be an unlikely explanation for our findings.   
 Third, it is possible that residual confounding may have influenced our estimates. 
However, we were able to control for previously identified risk factors for early 
menopause such as smoking, vegetable protein intake, and BMI. None of the covariates 
included in multivariable models produced a >10% change in exposure estimates and 
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unadjusted estimates were similar to fully adjusted estimates, suggesting that substantial 
bias due to residual confounding is unlikely.  
 There are also several important strengths of our study to highlight. First, this was 
the first study to evaluate the association of 25(OH)D and early menopause. Not only did 
we assess total 25(OH)D, we also evaluated vitamin D binding protein and free 
25(OH)D, which represents the biologically active vitamin D fraction and has been more 
strongly related to risk of some health outcomes than total 25(OH)D alone. Second, the 
size of our study population was larger than previous studies evaluating 25(OH)D and 
AMH, which provided higher statistical power and also allowed us to consider a wide 
variety of potential confounders. Finally, as most previous studies of 25(OH)D and AMH 
have been conducted among women seeking treatment for infertility, we anticipate that 
our findings are more widely generalizable to healthy premenopausal women. In the 
context of our findings and those of the aforementioned studies, it appears that 25(OH)D 
is unlikely to be related to AMH or early menopause, at least among White 
premenopausal women without vitamin D deficiency.  
 In conclusion, the findings of our study do not suggest that 25(OH)D levels are 
importantly related to risk of early menopause. Modest positive associations of VDBP 
levels with risk of early menopause and AMH levels warranted further evaluation in 
large, ethnically diverse populations.  
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Table 3.1 Characteristics of early menopause cases and controls at blood draw 
(1996-1999): Nurses' Health Study II 
Characteristica Cases (n=328) Controls (n=328) Pb 
Age (y)c 40.2 (2.8) 40.2 (2.8) 0.99 
BMI (kg/m2) 25.4 (0.3) 25.0 (0.3) 0.10 
Age at menarche (y) 12.4 (0.1) 12.3 (0.1) 0.57 
Physical activity (MET-h/wk) 81.5 (14.7) 72.5 (12.9) 0.12 
Parity 1.8 (0.1) 1.9 (0.1) 0.55 
Duration of breastfeeding (mo) 4.8 (0.2) 5.0 (0.2) 0.25 
Alcohol intake (g/d) 3.3 (0.3) 3.9 (0.4) <0.01 
Vegetable protein intake (% of total kcal/day) 5.2 (0.01) 5.5 (0.01) 0.09 
Total vitamin D intake (IU/d) 348 (13.3) 381 (15.1) 0.03 
Supplemental vitamin D intake 125 (10.9) 156 (11.7) 0.19 
Dietary vitamin D intake 218 (6.5) 217 (6.4) 0.81 
Dairy vitamin D intake 122 (6.2) 118 (5.7) 0.15 
Total calcium intake (mg/d) 990 (24.5) 1062 (27.6) 0.03 
Supplemental calcium intake 146 (15.7) 186 (19.7) <0.001 
Dietary calcium intake 841 (18.3) 865 (17.1) 0.29 
Dairy calcium intake 537 (18.6) 542 (17.3) 0.27 
Non-Hispanic White (%) 95.3 98.8 0.01 
Season of blood draw (%)   0.64 
Summer/fall 50.0 50.0  
Winter/spring 51.8 48.2  
Current smoker (%) 14.0 9.2 0.05 
Smoking duration (pack-years)d 12.9 (1.0) 10.5 (0.7) 0.02 
Current OC user (%) 1.8 3.7 0.15 
OC use duration (mo)e 59.6 (3.2) 63.3 (3.5) 0.11 
aValues are means (SE) unless otherwise indicated. 
bP-values correspond to t-tests for continuous variables and chi-square tests for categorical variables.  
cValues are means (SD). 
dAmong ever smokers only.    
eAmong ever OC users only.   
 
  
Table 3.2 ORs (95% CIs) for early menopause according to quartile of total and free 25(OH)D and vitamin D 
binding protein levels: Nurses’ Health Study II (1996-2011) 
Biomarker Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-valued Continuouse 
Total 25(OH)D       
Median (nmol/L) 44.2 59.8 71.7 90.4   
Cases: Controls 86:83 92:83 71:82 79:80   
Unadjusted ORa (95% CI) 1 1.07 (0.70-1.64) 0.81 (0.51-1.29) 0.91 (0.56-1.48) 0.69 1.02 (0.83-1.25) 
MV1b OR (95% CI) 1 1.21 (0.75-1.93) 0.93 (0.56-1.54) 1.04 (0.60-1.81) 0.75 1.12 (0.89-1.42) 
MV2c OR (95% CI) 1 1.18 (0.73-1.89) 0.88 (0.53-1.46) 0.96 (0.55-1.69) 0.70 1.09 (0.85-1.38) 
Free 25(OH)D       
Median (pmol/L) 13.9 18.7 24.2 32.4   
Cases: Controls 94:83 91:85 81:80 62:80   
Unadjusted ORa (95% CI) 1 0.92 (0.60-1.40) 0.87 (0.56-1.34) 0.65 (0.41-1.05) 0.32 0.82 (0.67-0.99) 
MV1b OR (95% CI) 1 1.02 (0.64-1.62) 0.98 (0.61-1.57) 0.70 (0.41-1.20) 0.44 0.85 (0.68-1.05) 
Vitamin D Binding Protein       
Median (µg/mL) 145.4 203.0 248.2 305.3   
Cases: Controls 56:81 87:81 86:83 99:83   
Unadjusted ORa (95% CI) 1 1.54 (0.99-2.41) 1.49 (0.96-2.34) 1.75 (1.11-2.77) 0.10 1.16 (0.99-1.36) 
MV1b OR (95% CI) 1 1.54 (0.94-2.51) 1.80 (1.10-2.95) 1.80 (1.09-2.98) 0.07 1.17 (0.99-1.39) 
MV2c OR (95% CI) 1 1.50 (0.92-2.46) 1.77 (1.08-2.90) 1.77 (1.06-2.94) 0.09 1.16 (0.98-1.38) 
aModel adjusted for matching factors only (i.e., age at blood collection (within 4 mo), time of day of blood collection, month of collection (within 3 mo), sample 
type (luteal phase or untimed) and fasting status). 
bMultivariable model 1 adjusted for matching factors + physical activity (<9, 9-<42, or ≥42 MET-h/wk), duration of breastfeeding at blood draw (0, >0-6, >6-18, 
>18 mo), smoking status at blood draw (non vs. current), BMI (<25 or ≥25 kg/m2), and intakes of alcohol (0, 0.1-9.9, 10.0-29.9, or ≥30.0 g/day) and percent of 
vegetable protein (continuous) at blood draw.   
cMultivariable model 2 adjusted for covariates in MV1 + mutual adjustment of total 25(OH)D and VDBP. 
dP-values correspond to likelihood ratio tests comparing models with and without indicator variables for exposures.   
eORs correspond to 1 standard deviation increase in exposure.  
 
 
 
69 
 70 
 
Table 3.3 Unadjusted and adjusted AMH geometric means (95% CIs) 
according to quartile of total and free 25(OH)D and vitamin D binding protein: 
Nurses’ Health Study II (1996-2011) 
  N Range 
Unadjusted AMH 
Geometric Mean (95% CI) 
(ng/mL) 
Adjusteda AMH 
Geometric Mean (95% CI) 
(ng/mL) 
Total 25(OH)D  nmol/L   
Q1 169 22.9-52.1 0.4 (0.3-0.6) 0.5 (0.4-5.8) 
Q2 175 52.2-65.8 0.4 (0.3-0.5) 0.4 (0.3-4.6) 
Q3 153 65.9-78.8 0.4 (0.3-0.5) 0.4 (0.3-5.4) 
Q4 159 78.8-159.0 0.4 (0.3-0.5) 0.4 (0.3-4.8) 
Pb   0.65 0.55 
     
Free 25(OH)D  pmol/L   
Q1 177 6.8-16.2 0.4 (0.3-0.5) 0.4 (0.3-0.5) 
Q2 176 16.3-21.4 0.4 (0.3-0.5) 0.4 (0.3-0.5) 
Q3 161 21.6-27.5 0.4 (0.3-0.5) 0.4 (0.3-0.5) 
Q4 142 27.5-88.9 0.5 (0.4-0.6) 0.5 (0.4-0.6) 
Pb   0.35 0.32 
     
VDBP  µg/mL   
Q1 137 48.7-177.7 0.5 (0.4-0.7) 0.5 (0.4-0.7) 
Q2 168 178.2-224.3 0.4 (0.3-0.5) 0.4 (0.3-0.6) 
Q3 169 224.8-272.0 0.4 (0.3-0.5) 0.4 (0.3-0.5) 
Q4 182 272.6-425.8 0.3 (0.3-0.4) 0.3 (0.3-0.4) 
Pb   0.07 0.04 
aMultivariable model 1 adjusted for matching factors + physical activity (<9, 9-<42, or ≥42 MET-h/wk), 
duration of breastfeeding at blood draw (0, >0-6, >6-18, >18 mo), smoking status at blood draw (non vs. 
current), BMI (<25 or ≥25 kg/m2), and intakes of alcohol (0, 0.1-9.9, 10.0-29.9, or ≥30.0 g/day) and percent of 
vegetable protein (continuous) at blood draw.   
cP-value corresponds to type III P-value. 
  
Table 3.4 ORs (95% CIs) for early menopause according to total 25(OH)D cutpoints: Nurses’ 
Health Study II (1996-2011) 
Total 25(OH)D  <50 nmol/L 50-74 nmol/L ≥75 nmol/L P-valuee 
Median (nmol/L) 43.0 63.2 87.5  
Cases: Controls 68:70 164:158 96:100  
Unadjusted ORa (95% CI) 1 1.07 (0.71-1.59) 0.98 (0.61-1.56) 0.89 
MV1b OR (95% CI) 1 1.29 (0.83-2.03) 1.15 (0.67-1.95) 0.50 
MV2c OR (95% CI) 1 1.25 (0.79-1.96) 1.08 (0.63-1.85) 0.56 
aModel adjusted for matching factors only (i.e., age at blood collection (within 4 mo), time of day of blood collection, month of collection 
(within 3 mo), sample type (luteal phase or untimed) and fasting status). 
bMultivariable model 1 adjusted for matching factors + physical activity (<9, 9-<42, or ≥42 MET-h/wk), duration of breastfeeding at blood 
draw (0, >0-6, >6-18, >18 mo), smoking status at blood draw (non vs. current), BMI (<25 or ≥25 kg/m2), and intakes of alcohol (0, 0.1-9.9, 
10.0-29.9, or ≥30.0 g/day) and percent of vegetable protein (continuous) at blood draw. 
cMultivariable model 2 adjusted for covariates in MV1 + mutual adjustment of total 25(OH)D and VDBP. 
eP-values correspond to likelihood ratio tests comparing models with and without indicator variables for exposures.   
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CHAPTER 4 
A PROSPECTIVE STUDY OF DAIRY FOOD INTAKE AND EARLY 
MENOPAUSE  
4.1 Abstract 
Early natural menopause, defined as the cessation of ovarian function prior to age 45, 
affects approximately 10% of women and increases risk of cardiovascular disease and 
other conditions. Laboratory evidence suggests a potential role of dairy foods in the 
ovarian aging process; however, no prior epidemiologic studies have evaluated how dairy 
intake is associated with risk of early menopause. We therefore evaluated how intakes of 
total, low-fat, high-fat and individual dairy foods are associated with early menopause in 
the Nurses’ Health Study II. Women who were premenopausal at the start of follow-up in 
1991 were followed until 2011 for early natural menopause. Food-frequency 
questionnaires were used to assess dietary intake. In Cox proportional hazards models 
adjusting for age, smoking, and other factors, total baseline dairy intake of ≥4 
servings/day versus <4 servings/week was associated with 23% lower risk of early 
menopause (95% confidence interval (CI) = 0.64, 0.93; P-trend = 0.08). Associations 
appeared to be limited to low-fat dairy foods (≥2 servings/day versus <3 servings/month 
HR = 0.83; 95% CI = 0.68, 1.01; P-trend = 0.02), whereas high-fat dairy intake was not 
associated with early menopause. Low-fat dairy foods may represent a modifiable risk 
factor to reduce risk of early menopause among premenopausal women.  
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4.2 Introduction 
Early natural menopause is defined as the cessation of ovarian function prior to 
age 45 and affects approximately 10% of women in Western populations. (1) Early 
menopause is associated with increased risk of several adverse health outcomes including 
cardiovascular disease, osteoporosis, depression, and early cognitive decline. (2–5) 
Furthermore, because female fertility declines substantially during the 10 years preceding 
the final menses, early menopause may also interfere with family planning. As women 
increasingly choose to delay childbearing until their later reproductive years, being 
unable to conceive as desired may have substantial psychological and financial 
implications. (1,6) Population-based studies indicate that genetic factors account for 
relatively little of the variation in menopausal timing and recent prospective studies have 
identified a number of modifiable risk factors for early menopause, including diet. 
(60,61,147) Bovine milk and dairy foods may be of particular interest, as they are 
comprised of a number of nutritive and non-nutritive components that may be 
physiologically related to ovarian aging and ovarian reserve. (unpublished manuscript; 
Purdue-Smithe et al., University of Massachusetts Amherst) 
 Milk is an excellent source of vitamin D and calcium, as well as other macro and 
micronutrients including dairy fat, dairy protein, lactose, vitamin A, B-vitamins, 
magnesium, phosphorus, potassium, and zinc. (65) Many of these nutrients, particularly 
vitamin D, have been hypothesized to be related to ovarian aging through potential 
effects on adiposity, inflammation, and anti-Müllerian hormone, a glycoprotein involved 
in follicle recruitment and a reliable proxy for ovarian reserve. (unpublished manuscript; 
Purdue-Smithe et al., University of Massachusetts Amherst) In addition, milk also 
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contains exogenous sex hormones including estrogens and progesterone. (66,87,185) The 
potential for dairy foods to influence levels of circulating hormones is supported by 
epidemiologic data suggesting that dairy consumption is positively associated with 
plasma levels of total and free estradiol. (86) 
 At this time, epidemiologic studies of milk and dairy consumption and menopause 
timing are scarce. We recently observed inverse associations of vitamin D and calcium 
intakes from food sources, particularly from dairy foods, and risk of early menopause in 
the Nurses’ Health Study II (NHS2). (60) However, in a subsequent analysis, we 
observed no association of plasma 25-hydroxyvitamin D levels and risk of early 
menopause raising questions about whether associations observed with dietary and dairy 
vitamin D intake are instead explained by other components of dairy. (unpublished 
manuscript; Purdue-Smithe et al., University of Massachusetts Amherst) Despite these 
data, to our knowledge, no prior studies have specifically evaluated how intakes of dairy 
foods are associated with risk of early menopause (i.e., before 45). In light of this gap, the 
aim of the present study was to evaluate risk of early menopause with respect to intakes 
of total, low-fat, high-fat, and individual dairy foods among participants of the NHS2.   
4.3 Subjects and Methods 
The NHS2 is a prospective study of 116,429 female U.S. registered nurses who 
were 25-42 years old in 1989 when they responded to a mailed baseline questionnaire. 
Information regarding lifestyle behaviors and medical conditions are collected through 
biennial questionnaires, for which the follow-up rate for each cycle has been at least 89%. 
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The study protocol was approved by the Institutional Review Board at Brigham and 
Women’s Hospital in Boston, MA.  
4.3.1 Assessment of early menopause 
On the 1989 baseline questionnaire, nurses were asked if their periods had ceased 
permanently with the following response options: 1) No: Premenopausal; 2) Yes: No 
menstrual periods; 3) Yes: had menopause but now have periods induced by hormones; 
and 4) Not sure; (e.g., started hormones prior to cessation of periods). Nurses who 
indicated that their periods had ceased were then asked the following questions: 1) At 
what age did your periods cease? (open response); and 2) For what reason did your 
periods cease? (response options were surgery; radiation or chemotherapy; and natural). 
Women were also asked about their current and past use of replacement sex hormones. 
Questions about menopausal status and replacement hormone therapy were repeated on 
all questionnaires thereafter. Age at natural menopause was defined as age after 12 
consecutive months of amenorrhea not due to radiation, chemotherapy or surgery. A 
small number of women reported being postmenopausal on one questionnaire and then 
subsequently reported being premenopausal. For these women, we defined age at 
menopause as age after which periods were absent for 12 months or more, and then 
confirmed that this status persisted for at least 3 consecutive questionnaires.  
We were interested in prospectively evaluating dairy intake and risk of early 
menopause; participants were thus eligible for inclusion in our study if they indicated 
being premenopausal and reported no age at menopause on the baseline 1989 
questionnaire (n = 108,812). We then excluded women who did not respond to or who 
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reported implausible caloric intake (<500 or ≥3,500 kcal/d) on the 1991 food-frequency 
questionnaire (FFQ) (n = 22,847), were diagnosed with cancer before 1991 (n = 391), or 
whose date of menopause was before their return date of the 1991 FFQ (n = 283). After 
baseline exclusions, 85,651 women comprised the analytic study sample.  
Women in the study sample were then followed prospectively until 2011 for self-
report of the cessation of menses, as defined above, or first report of hysterectomy, bi-
lateral or unilateral oophorectomy, cancer (not including non-melanoma skin cancer), 
loss to follow-up, or death. We identified cases of early menopause as women who 
reported natural menopause occurring before the age of 45.  
4.3.2 Dietary assessment 
Nurses were queried about their usual intake of 131 foods, beverages, and 
supplements over the preceding year via validated semi-quantitative FFQs in 1991, 1995, 
1999, 2003, 2007, and 2011. (159–161) These FFQs asked participants to estimate, on 
average, how often they consumed specific foods and beverages. Participants reported 
their usual consumption by indicating one of nine frequency categories for each food and 
beverage (i.e., <1 serving/month, 1-3 servings/month, 1, 2-4, 5-6 servings/wk, and 1, 2-3, 
4-5, and ≥6 servings/d). Specific dairy foods assessed by the FFQs included skim/low-fat 
milk, whole milk, cream, frozen yogurt/sherbet, yogurt, cottage/ricotta cheese, ice cream, 
cream cheese, other cheese, and butter. Total dairy intake was calculated by summing 
intakes of all dairy products. We calculated low-fat dairy intake by summing intakes of 
skim and non-fat milk, frozen yogurt/sherbet, yogurt, cottage/ricotta cheese, and other 
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low-fat cheese. High-fat dairy intake was equal to the sum of whole milk, cream, ice 
cream, cream cheese, other high-fat cheese, and butter intakes.  
The validity of the FFQ was assessed by a comparison to 1-week diet records 
among a random subset (n = 173) of women in the Nurses’ Health Study, a comparable 
population of female health professionals. For dairy foods, the Pearson correlation 
coefficients comparing the FFQ to a 1-week diet record were moderate to strong (range = 
0.54-0.77), with the exception of hard cheese (r = 0.33). (160) 
In 1998, 45,947 nurses completed a retrospective 124-item food frequency 
questionnaire that assessed their usual diet in high school. Dairy foods assessed on this 
questionnaire included chocolate milk, whole milk, low-fat milk, skim milk, yogurt, 
cottage or ricotta cheese, cheese, cream cheese, and butter. Total adolescent dairy intake 
was calculated as the sum of intakes of these foods. The reproducibility of this FFQ was 
assessed by a comparison to a subsequent FFQ assessing high school diet that was 
administered in 2002 to a subset of nurses who completed the initial FFQ (n=333). 
Reproducibility between the two questionnaires was high for dairy foods (r=0.64) and for 
milk specifically (r=0.76). (186) 
4.3.3 Assessment of covariates 
Information regarding age, race, height, ethnicity, maternal and paternal education 
level, physical activity during high school, body mass index at age 18, smoking during 
high school, and age at menarche was collected at baseline in 1989. Updated information 
on weight, parity, oral contraceptive use, breastfeeding, hormone therapy use, and 
smoking were collected biennially throughout follow-up. Baseline height and updated 
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weight were used to calculate updated body mass index (BMI) as weight (kg)/ height 
(m)2 for each questionnaire cycle. Information on physical activity was collected in 1991, 
1997, 2001, 2005, and 2009 using nurses’ responses to questions regarding average time 
spent per week participating in specific activities (i.e., walking, running, biking, etc.), 
from which we calculated metabolic equivalent task (MET)-hours per week. (163) 
Intakes of vegetable protein and alcohol were assessed via FFQ every four years 
beginning in 1991. Intakes of other nutrients present in dairy foods including dairy 
protein, lactose, dairy fat, dietary magnesium, phosphorus, potassium, zinc, vitamins B1, 
B2, B5 and B12, folate, calcium, vitamin D, and vitamin A were also estimated using these 
FFQs. For example, calcium intake from food sources was estimated by summing 
calcium content per 1 serving of each food and beverage (i.e., skim, low-fat, and whole 
milk, yogurt, hard cheese, cottage cheese, spinach, etc.) and multiplying it by the 
frequency of consumption. Intakes of vitamin D, vegetable protein, alcohol, and other 
nutrients were derived in a similar manner. We calculated percentage of total kcal from 
vegetable protein by multiplying grams of vegetable protein by 4 kcal/g and then dividing 
by total kcal.  
Nurses were also asked to indicate their average use and dosage of multivitamins, 
calcium and vitamin D supplements every two years on FFQs or biennial questionnaires, 
which we used to estimate intakes of each nutrient from supplement sources. Total 
vitamin D and calcium intakes were then calculated by summing estimated dietary and 
supplemental intakes of each nutrient. We adjusted intakes of all nutrients for total energy 
using the residual method. (162) 
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4.3.4 Statistical analysis 
 We divided participants into categories of total dairy food intake and assessed 
baseline characteristics of our study sample according to category of total dairy food 
intake in 1991 using age-adjusted generalized linear models. 
 We then used Cox proportional hazards regression to estimate age-adjusted and 
multivariable hazard ratios (HR) for early menopause according to category of adult 
intake of total, high-fat, low-fat, and individual dairy foods. We repeated these analyses 
for adolescent intakes of total dairy and individual dairy foods. Tests for linear trend were 
conducted by modeling each exposure as a continuous servings/day variable. Participants 
contributed person-time (in months) beginning on the date of return of the 1991 
questionnaire until menopause, first report of hysterectomy, bi-lateral or unilateral 
oophorectomy, cancer (not including non-melanoma skin cancer), loss to follow-up, or 
death, whichever occurred first. Analyses were stratified on age (in months) and 
questionnaire cycle.  
We were interested in assessing potential variation in associations according to 
timing of exposure assessment and therefore modeled timing of intake using both 
baseline (1991) intake variables and cumulative average intake for each exposure. 
Cumulative average values for each exposure were calculated as mean intakes estimated 
from all FFQs up to and including the cycle prior to menopause.  
There was very little evidence of confounding in our analyses, and thus covariate 
selection for multivariable models (MV1) was based on factors identified a priori (i.e., 
age, race/ethnicity, parity, multivitamin use, age at menarche, and physical activity) and 
factors previously identified as risk factors for early menopause in our population (i.e., 
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smoking, BMI, duration of breastfeeding, and intakes of alcohol and vegetable protein). 
To assess whether estimates for dairy exposures may be confounded by intakes of 
vitamin D and calcium, which are associated with early menopause in NHS2, we 
additionally adjusted for intakes of total vitamin D and calcium in a second multivariable 
model (MV2). We also conducted analyses in which we further adjusted total dairy intake 
for intakes of dairy protein, lactose, dairy fat, dietary magnesium, phosphorus, potassium, 
zinc, vitamins B1, B2, B5 and B12, folate, and vitamin A in order to evaluate whether 
nutritive versus non-nutritive components of dairy may be more strongly associated with 
risk of early menopause. In multivariable models assessing adolescent dairy intake, we 
adjusted for factors identified a priori as potential confounders, including age, 
race/ethnicity, physical activity during high school, BMI at age 18, and smoking during 
high school.  
 We considered potential effect modification by BMI (underweight/normal vs. 
overweight/obese) and OC use (ever vs. never) on the total dairy-early menopause 
relation using likelihood ratio tests comparing models with and without multiplicative 
interactions terms. 
We conducted a number of sensitivity analyses to evaluate the robustness of our 
estimates to potential residual confounding. Because some evidence suggests that 
polycystic ovary syndrome (PCOS) is related to both dairy intake and menopausal 
timing, we conducted analyses excluding women diagnosed with PCOS (n = 1,852). 
(187,188) We also conducted analyses restricted to women without diagnoses of 
autoimmune conditions including rheumatoid arthritis, multiple sclerosis, lupus, Crohn’s 
disease, and ulcerative colitis, as these conditions are associated with earlier age at 
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menopause (189) and could be related changes in diet (n = 1,895). Furthermore, in order 
to assess the adequacy of our control for confounding by smoking, we restricted an 
analysis to never smokers (n = 1,226). Finally, we considered the possibility that medical 
conditions leading to hysterectomy may have also been related to dairy intake, and 
conducted analyses censoring at date of laparoscopy-confirmed endometriosis and 
ultrasound-confirmed uterine fibroid diagnosis in order to evaluate this potential selection 
bias. 
All statistical analyses were conducted with SAS v9.4 software (SAS Institute 
Inc., Cary, NC). We used two-sided statistical tests performed at the 0.05 significance 
level for all analyses. 
4.4 Results 
Over 20 years of follow-up, 2,049 women in our study sample experienced early 
menopause. Age-adjusted baseline characteristics according to category of total dairy 
intake are presented in Table 4.1. At baseline, women reporting the highest dairy were on 
average younger, more physically active, less likely to smoke, and had higher BMI than 
those reporting the lowest intake. Dairy intake was also positively associated with, 
calcium, vitamin D and alcohol and inversely associated with vegetable protein intake.  
In age-adjusted analyses, women who consumed ≥4 servings of total dairy per 
day versus <4 servings/week experienced a 26% (95% CI: 0.62-0.88) lower risk of early 
menopause (Table 4.2). In particular, women who consumed the most low-fat dairy foods 
(≥2 servings/day) were 24% (95% CI: 0.64-0.91) less likely to experience early 
menopause compared to women with the lowest intake (<3 servings/month). In contrast, 
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no association was observed for high-fat dairy intake (≥2 servings/day vs. <3 
servings/month HR: 1.03; 95% CI: 0.87-1.23). 
After adjusting for BMI, smoking, and other factors in multivariable model 1 
(MV1), estimates for total and low-fat dairy intake were very similar, but slightly 
attenuated (Table 4.2). After further adjustment for total vitamin D and calcium intake in 
a second multivariable model (MV2), the HR comparing ≥4 per day versus <4 servings 
of total dairy per week was 0.77 (95% CI: 0.64-0.93). Each 1 serving/day higher intake of 
total dairy was associated with a marginally significant 3% (95% CI: 0.94-1.00; P-trend = 
0.08) lower risk. Specifically, high (≥2 servings/day) versus low (<3 servings/month) 
intake of low-fat dairy foods was associated with 17% (95% CI: 0.68-1.01) lower risk of 
early menopause, and each 1 serving/day higher was associated with 5% (95% CI: 0.91-
0.99; P = 0.02) lower risk. Similar to estimates from age-adjusted models, intake of high-
fat dairy was not associated with risk of early menopause in multivariable analyses (<3 
servings/month versus ≥2 servings/day MV2 HR: 1.03; 95% CI: 0.87-1.23). To evaluate 
potential confounding of low-fat dairy by high-fat dairy intake and vice versa, we also 
mutually adjusted these exposures in a third multivariable model (data not shown). 
Estimates from these models were substantively unchanged. Adjusting total dairy intake 
for intakes of dairy protein, lactose, dairy fat, dietary magnesium, phosphorus, potassium, 
zinc, vitamins B1, B2, B5 and B12, folate, and vitamin A did not meaningfully change the 
estimates for exposures (results not shown). 
Our findings for total and low-fat dairy intake were consistent with those for low-
fat dairy foods including skim milk and yogurt. For example, in fully adjusted models 
(MV2), each 1 serving per day of skim milk was associated with 6% (95% CI: 0.89-0.99; 
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P-trend = 0.02) lower risk of early menopause. Likewise, high (≥2 servings/day) versus 
low (almost never) intake of yogurt was associated with 14% (95% CI: 0.75-0.98) lower 
risk of early menopause (Table 4.4), although the P-trend was not significant (P-trend = 
0.19). Other individual dairy foods were not significantly associated with risk of early 
menopause.  
To evaluate how dairy intake over longer periods of time may be associated with 
early menopause, we also conducted analyses in which we modeled cumulative average 
intake of exposures. Estimates from these models were similar to those of baseline (1991) 
exposures, but attenuated slightly. For example, in models evaluating cumulative average 
intake, each 1 serving/day increase in total dairy and low-fat dairy intake was associated 
with 2% (95% CI: 0.94-1.01; P-trend = 0.15) and 5% (95% CI: 0.90-1.00; P-trend = 0.04) 
lower risk of early menopause, respectively (complete data not shown).  
Our findings for adolescent intake of dairy foods and risk of early menopause 
among the subset (n=1,012) of women who completed high school diet questionnaires are 
presented in Table 4.3. Dairy intake was substantially higher during adolescence (median 
= 10 servings/d) than adulthood (median = 2 servings/d) and therefore ranges were not 
comparable between time periods. Although analyses of dairy intake during adolescence 
were ultimately underpowered, estimates were similar to those for adult dairy intakes. For 
example, in multivariable analyses adjusting for BMI at age 18, smoking in high school, 
and other factors, the HR comparing total adolescent dairy intake of ≥6 versus <4 
servings/d was 0.86 (95% CI: 0.66-1.12). We also conducted analyses including total 
dairy intake during adolescence and at baseline (1991) in the same model to evaluate 
whether adolescent dairy intake may be differently related to early menopause risk than 
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adult dairy intake. Estimates for exposures at both time periods were similar but slightly 
stronger after mutual adjustment.  
Analyses restricted to women without PCOS or autoimmune conditions and 
women who never smoked produced estimates similar to those among the full population. 
There was no evidence of multiplicative interaction by OC use (P-interaction = 0.53) or 
BMI (P-interaction = 0.68) on the total dairy-early menopause relation.   
4.5 Discussion 
In this prospective study, we found intake of low-fat dairy foods to be inversely 
associated with risk of early menopause. The observed inverse association of low-fat 
dairy intake appears to be strongly related to intakes of skim milk and yogurt, as these 
foods, but not others, were associated with lower risk of early menopause. We also 
observed some suggestion of a possible inverse association of risk with low-fat dairy 
intake in adolescence, though lower sample size for these analyses limited our statistical 
power. In contrast, high-fat dairy intake at either time point did not appear related to risk. 
To our knowledge, this is the first study to evaluate how dairy consumption is 
specifically related to risk of early menopause. However, our findings are largely 
consistent with those of a recent prospective study evaluating dairy and overall 
menopause timing. In this study, Carwile et al observed that low-fat dairy and skim milk 
intakes, but not total or high-fat dairy intake, were associated with earlier age at 
menopause only among participants of the NHS who were <51 years of age. (8) 
Conversely, Nagel et al observed no association of total dairy intake and age at 
menopause among 5,110 participants of the EPIC cohort. (131) The inconsistency of our 
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findings for total dairy intake versus those of Carwile and Nagel is notable, but may be 
explained by overall higher intakes of high-fat dairy in these populations.  
A number of different mechanisms relating constituents of dairy to ovarian aging 
have been proposed, including upregulation of anti-Müllerian hormone by vitamin D and 
potential effects on vitamin D-mediated inflammatory pathways. (unpublished 
manuscript; Purdue-Smithe et al., University of Massachusetts Amherst) In our recent 
analyses, we observed that vitamin D and calcium intakes from food sources, specifically 
from dairy foods, were associated with lower risk of early menopause among participants 
of the NHS2. (60) We subsequently found that plasma 25(OH)D levels were not 
associated with risk of early menopause or AMH levels in our population, suggesting that 
our findings are more likely to be explained by mechanisms involving other components 
of milk, rather than those involving vitamin D. (unpublished manuscript; Purdue-Smithe 
et al., University of Massachusetts Amherst) 
Alternatively, the observed associations may be explained by alterations in sex 
hormone levels by non-nutritive components of dairy. Milk products contain varying 
concentrations of conjugated and unconjugated estrogen metabolites and progesterone. 
(66,185) Higher concentrations of lipophilic unconjugated estrogens and progesterone are 
present in high-fat dairy products, whereas hydrophilic conjugated estrogens are more 
concentrated in low-fat dairy products. (86,185) Hydrophilic conjugated estrogen 
metabolites, such as estrone sulfate, are considered to be more biologically active than 
their unconjugated counterparts due to their circumvention of hepatic metabolism. (84) 
Differences in our findings for low-fat and high-fat dairy intake may thus be explained by 
 86 
 
the relative bioavailability and concentration of these hormones depending upon milk fat 
content.  
Milk also contains androgens such as testosterone and androstenedione, which 
may be implicated in ovarian aging. (87) Epidemiologic evidence suggests that 
exogenous androgens are positively associated with circulating insulin-like growth factor 
1 (IGF-1) in humans. (88) Age is associated with a decrease in circulating IGF-1, and 
studies in rats have observed that low IGF-1 is associated with disruption of luteinizing 
hormone, which regulates ovulation. (8,93) Dairy consumption may therefore increase 
levels of IGF-1, potentially allowing for the continuation of normal menstrual cycles 
during the later reproductive years. 
The potential for dairy food intake to influence levels of hormones in humans is 
evidenced by epidemiologic studies showing that consumption of dairy products is 
positively associated with plasma levels of total and free estradiol and IGF-1. 
(86,89,90,92) Indeed, milk intake has been associated with other reproductive outcomes 
including endometriosis (13) and premenstrual syndrome (63), as well as acne (190), 
suggesting that the levels of hormones present in dairy are sufficient to alter circulating 
levels and in turn, possibly influence risk of health outcomes. Given that associations for 
low-fat dairy intake persisted after we controlled for vitamin D and calcium intakes, as 
well as other nutrients in milk, the mechanisms involving hormones in milk seem to be 
the most likely physiologic explanation for our findings.  
Strengths of our study include large sample size, prospective design, and high 
retention of participants throughout the duration of follow-up (>89%). Our study also has 
several limitations to note. First, we used nurses’ self-report of age at menopause to 
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classify cases and non-cases. Some women may have misreported their age at 
menopause, resulting in misclassification of case status. However, self-reported 
menopausal status has been shown to be a reproducible method of assessment over 
multiple questionnaire cycles in a comparable population of female nurses. (168) Among 
6,591 NHS women who were premenopausal in 1976 and reported having natural 
menopause on the 1978 questionnaire, 82% reported their age at menopause to within 1 
year on the following two questionnaires, suggesting that our findings are likely robust to 
substantial misclassification of outcome. Importantly, any misclassification of case status 
is unlikely to be related to dairy intake and would not explain our positive findings. 
Second, some degree of non-differential misclassification due to error in self-reported 
dairy food intake is expected. However, misclassification across extreme categories of 
dairy intake is improbable and would likely produce a bias towards the null.  
Finally, estimates for exposures assessed at baseline were stronger than those in 
cumulative average models, perhaps suggesting that dairy intake may be more strongly 
related to early menopause risk at younger ages. However, we were unable to assess valid 
age-specific estimates for updated adult dairy intake and early menopause due to models 
that used age as the underlying time variable to evaluate an age-dependent outcome. 
There are also limitations specific to our analyses of adolescent intakes of dairy. 
Although estimates from models evaluating adolescent intake of total dairy are similar to 
those of adult intakes, our ability to make direct comparisons across time periods is 
limited due to lower sample size for adolescent and childhood analyses and substantially 
higher overall total dairy intake levels. Also, intake levels of dairy during adolescence 
and adulthood were highly correlated in our population, making it difficult to 
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differentiate temporally whether observed associations for each time point are 
independent. Future large prospective studies may be more adequately powered to 
evaluate how early life dairy intake may be associated with risk of early menopause.  
The NHS2 is a heterogeneous population with regard to many lifestyle and dietary 
variables; we therefore anticipate that our findings would apply to similar groups of 
premenopausal women. However, our findings may not be applicable to women who 
cannot consume dairy products due to milk allergies or lactose-intolerance. Findings of 
our study indicate that low-fat dairy products including skim milk and yogurt may 
represent modifiable risk factors for women to reduce risk of early menopause.  
 
  
 
Table 4.1 Age-adjusted characteristics of premenopausal women according to category of total dairy intake at 
baseline (1991): Nurses’ Health Study II, 1991a 
 Total Dairy Intake (servings) 
Characteristic <2/wk (n=2091) 2-4/wk (n=5334) 5-6/wk (n=6062) 1/d (n=28419) 2-3/d (n=32429) ≥4/d (n=11899) 
Age, y b 36.8 (4.5) 36.5 (4.6) 36.3 (4.6) 36.0 (4.6) 35.6 (4.6) 35.2 (4.5) 
BMI, kg/m2 24.1 (0.1) 24.5 (0.1) 24.5 (0.01) 24.5 (0.03) 24.5 (0.03)  24.6 (0.05) 
Calcium intake, mg/d 711 (8.5) 728 (5.3) 785 (5.0) 894 (2.3) 1127 (2.2) 1304 (3.6) 
Vitamin D intake, IU/d 302 (5.6) 295 (3.5) 318 (3.3) 349 (1.5) 428 (1.4) 476 (2.3) 
Age at menarche, y 12.4 (0.03) 12.4 (0.02) 12.4 (0.02) 12.4 (0.01) 12.4 (0.01) 12.5 (0.01) 
Full-term pregnancies, n 1.4 (0.03) 1.4 (0.02) 1.5 (0.02) 1.5 (0.01) 1.6 (0.01) 1.7 (0.01) 
Physical activity, MET-h/wk 22.3 (1.4) 21.4 (0.9) 22.7 (0.8) 23.7 (0.4) 24.7 (0.4) 26.7 (0.6) 
Vegetable protein intake, % of 
total kcal 5.6 (0.02) 5.3 (0.01) 5.2 (0.01) 5.1 (0.01) 4.9 (0.01) 4.6 (0.01) 
Alcohol intake, g/d 2.6 (0.1)  3.0 (0.1) 3.2 (0.1) 3.2 (0.04) 3.1 (0.03) 3.3 (0.1) 
Ever used OCs, % 82 85 85 85 84 82 
Current smoker, % 17 15 14 12 10 12 
aValues are means ± SEs or percentages, unless otherwise indicated. All characteristics were calculated with the use of generalized linear models 
adjusted for the age of participants in 1991. MET-h, metabolic equivalent task hours; Q, quintile. 
bValues are means ± SDs. 
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Table 4.2 HRs (95% CIs) for early menopause by category of baseline 
(1991) intake of total, high-fat and low-fat dairy, and individual dairy 
foods: Nurses' Health Study II (1991-2011) 
  Cases Age-adjusted HR (95% CI) 
MV1a HR        
(95% CI) 
MV2b HR        
(95% CI) 
Total dairy      
≤4/wk 214 1 1 1 
5-6/wk 160 0.92 (0.75-1.13) 0.94 (0.77-1.16) 0.94 (0.76-1.15) 
1/d 673 0.81 (0.69-0.94) 0.84 (0.72-0.98) 0.83 (0.71-0.98) 
2-3/d 736 0.75 (0.65-0.88) 0.81 (0.70-0.95) 0.80 (0.68-0.93) 
≥4/d 266 0.74 (0.62-0.88) 0.79 (0.66-0.95) 0.77 (0.64-0.93) 
     
per 1 serving/d  0.96 (0.94-0.99) 0.98 (0.95-1.01) 0.97 (0.94-1.00) 
P  0.01 0.1 0.08 
     
High-fat dairy     
<3/m 297 1 1 1 
1/wk 451 1.00 (0.86-1.15) 1.03 (0.89-1.19) 1.03 (0.89-1.19) 
2-4/wk 441 0.92 (0.79-1.07) 0.96 (0.83-1.12) 0.96 (0.83-1.12) 
5-6/wk 212 0.93 (0.78-1.11) 0.98 (0.82-1.17) 0.98 (0.82-1.17) 
1/d 413 0.96 (0.83-1.11) 1.00 (0.86-1.17) 1.00 (0.86-1.17) 
≥2/d 235 1.03 (0.87-1.23) 1.03 (0.87-1.22) 1.03 (0.87-1.23) 
     
per 1 serving/d  1.01 (0.97-1.06) 1.00 (0.96-1.04) 1.00 (0.96-1.05) 
P  0.51 0.85 0.83 
     
Low-fat dairy      
<3/m 158 1 1 1 
1/wk 242 0.97 (0.79-1.19) 1.01 (0.83-1.24) 1.01 (0.83-1.24) 
2-4/wk 316 0.92 (0.76-1.12) 0.99 (0.81-1.20) 0.98 (0.81-1.19) 
5-6/wk 167 0.81 (0.65-1.01) 0.87 (0.70-1.09) 0.86 (0.69-1.08) 
1/d 618 0.80 (0.67-0.95) 0.88 (0.74-1.05) 0.86 (0.72-1.03) 
≥2/d 548  0.76 (0.64-0.91) 0.87 (0.72-1.04) 0.83 (0.68-1.01) 
     
per 1 serving/d  0.93 (0.90-0.97) 0.96 (0.93-1.00) 0.95 (0.91-0.99) 
P  <0.01 0.05 0.02 
     
Low-fat dairy foods     
Skim milk      
per 1 serving/d  0.92 (0.88-0.97) 0.96 0.91-1.00) 0.94 (0.89-0.99) 
P  <0.01 0.04 0.02 
     
Yogurt     
per 1 serving/d  0.86 (0.71-1.04) 0.88 (0.73-1.07) 0.88 (0.72-1.07) 
P  0.13 0.19 0.19 
     
Frozen yogurt/sherbet    
per 1 serving/d  0.91 (0.74-1.11) 0.95 (0.78-1.16) 0.95 (0.78-1.16) 
P  0.35 0.61 0.61 
     
Cottage/ricotta cheese    
per 1 serving/d  1.01 (0.76-1.36) 1.08 (0.81-1.43) 1.08 (0.81-1.43) 
P  0.92 0.61 0.61 
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Low-fat other cheese     
per 1 serving/d  1.00 (0.84-1.20) 1.03 (0.86-1.22) 1.03 (0.86-1.23) 
P  0.97 0.79 0.78 
     
High-fat dairy foods     
Whole milk     
per 1 serving/d  1.09 (0.96-1.23) 1.05 (0.92-1.19) 1.05 (0.92-1.19) 
P  0.19 0.46 0.46 
     
     
Cream     
per 1 serving/d  1.04 (0.97-1.11) 1.00 (0.94-1.07) 1.00 (0.94-1.07) 
P  0.26 0.97 0.96 
     
     
Ice cream     
per 1 serving/d  0.81 (0.62-1.04) 0.91 (0.72-1.17) 0.92 (0.72-1.17) 
P  0.09 0.47 0.47 
     
     
Cream cheese     
per 1 serving/d  0.83 (0.59-1.18) 0.88 (0.63-1.24) 0.88 (0.63-1.24) 
P  0.31 0.47 0.48 
     
High-fat other cheese     
per 1 serving/d  1.00 (0.90-1.11) 1.04 (0.94-1.16) 1.04 (0.94-1.16) 
P  0.99 0.46 0.44 
     
Butter     
per 1 serving/d  1.01 (0.91-1.11) 0.99 (0.89-1.09) 0.99 (0.89-1.08) 
P   0.92 0.78 0.78 
aMV1 model adjusted for age (months; continuous), pack-years of smoking (0-10, 11-20, or 
≥21), BMI (in kg/m2; <18.5, 18.5 to <25, 25 to <30, or ≥30), age at menarche (continuous), 
parity (nulliparous, 1-2, or ≥3), breastfeeding duration (continuous), percentage of total kcal 
from vegetable protein (quintiles 1-3 or 4+5), alcohol intake (<10 or ≥10 g/d), and current 
multivitamin use (yes or no).  
bMV2 model adjusted for MV1 covariates + total vitamin D intake (continuous) and total 
calcium intake (continuous).  
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Table 4.3 HRs (95% CIs) for early menopause by category of 
adolescent intake of total and individual dairy foods: Nurses' 
Health Study II (1991-2011) 
  Cases Age-adjusted HR (95% CI) 
MV1b HR        
(95% CI) 
Total dairy     
<4/d 60 1 1 
4-5/d 112 0.92 (0.67-1.27) 0.93 (0.68-1.28) 
6+/d 840 0.86 (0.66-1.11) 0.86 (0.66-1.12) 
    
per 1 serving/d  1.00 (0.99-1.01) 1.00 (0.99-1.01) 
P  0.60 0.64 
    
Skim milk     
Almost never 748 1 1 
1/m-1/d 135 0.90 (0.74-1.08) 0.92 (0.76-1.11) 
2+/d 129 0.89 (0.74-1.08) 0.92 (0.76-1.11) 
    
per 1 serving/d  0.95 (0.89-1.02) 0.96 (0.90-1.03) 
P  0.17 0.29 
    
Whole milk    
Almost never 414 1 1 
1/m-6/wk 207 1.10 (0.92-1.30) 1.07 (0.90-1.27) 
1/d 118 0.99 (0.81-1.22) 0.98 (0.80-1.20) 
2+/d 273 1.02 (0.87-1.19) 1.01 (0.86-1.18) 
    
per 1 serving/d  1.00 (0.95-1.05) 1.00 (0.95-1.05) 
P  0.95 0.89 
bMultivariable model 1 adjusted for age (continuous months), race (white or non-
white), physical activity during high school (continuous MET-h/wk), BMI at age 18 
(continuous kg/m2), and smoking during high school (continuous pack-years). 
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Table 4.4 HRs (95% CIs) for early menopause by category of baseline 
(1991) intake of individual dairy foods: Nurses’ Health Study II (1991-2011) 
 Cases Age-adjusted HR (95% CI) 
MV1a HR        
(95% CI) 
MV2b HR        
(95% CI) 
Skim milk      
Almost never 324 1 1 1 
1-3/m 168 0.97 (0.80-1.17) 1.00 (0.83-1.20) 1.00 (0.82-1.20) 
1/wk 161 1.08 (0.89-1.30) 1.12 (0.92-1.35) 1.11 (0.92-1.35) 
2-4/wk 322 0.81 (0.69-0.94) 0.85 (0.73-0.99) 0.85 (0.72-0.99) 
5-6/wk 161 0.81 (0.67-0.98) 0.85 (0.71-1.03) 0.84 (0.69-1.02) 
1/d 471 0.83 (0.72-0.95) 0.89 (0.77-1.03) 0.88 (0.76-1.01) 
2-3/d 399 0.74 (0.64-0.86) 0.83 (0.71-0.96) 0.79 (0.67-0.93) 
≥4/d 43 0.91 (0.66-1.25) 1.03 (0.75-1.42) 0.96 (0.69-1.35) 
     
P  <0.01 0.04 0.02 
     
Whole milk     
Almost never 1656 1 1 1 
1-3/m 171 1.05 (0.90-1.23) 1.02 (0.87-1.20) 1.02 (0.87-1.20) 
1-4/wk 46 1.08 (0.91-1.28) 1.03 (0.87-1.22) 1.03 (0.87-1.22) 
≥5/wk 76 1.05 (0.83-1.32) 0.98 (0.78-1.23) 0.98 (0.78-1.23) 
     
P  0.19 0.46 0.46 
     
Cream     
Almost never 1441 1 1 1 
1-3/m 297 0.95 (0.84-1.08) 0.97 (0.85-1.10) 0.97 (0.85-1.10) 
1/wk 67 0.99 (0.77-1.27) 1.01 (0.79-1.29) 1.01 (0.79-1.29) 
2-4/wk 70 1.06 (0.84-1.35) 1.06 (0.84-1.35) 1.06 (0.84-1.35) 
≥5/wk 174 1.05 (0.90-1.23) 0.99 (0.85-1.16) 0.99 (0.85-1.16) 
     
P  0.26 0.97 0.96 
     
Frozen yogurt/sherbet    
Almost never 682 1 1 1 
1-3/m 739 0.96 (0.86-1.06) 1.00 (0.90-1.11) 1.00 (0.90-1.11) 
1/wk 315 0.94 (0.82-1.07) 1.00 (0.87-1.14) 1.00 (0.87-1.14) 
≥2/wk 313 0.94 (0.82-1.07) 0.99 (0.87-1.13) 0.99 (0.87-1.14) 
     
P  0.35 0.61 0.61 
     
Ice cream     
Almost never 611 1 1 1 
1-3/m 862 1.01 (0.91-1.11) 1.06 (0.95-1.18) 1.06 (0.95-1.18) 
1/wk 346 0.99 (0.87-1.13) 1.08 (0.94-1.23) 1.08 (0.94-1.23) 
≥2/wk 230 0.89 (0.76-1.03) 0.98 (0.84-1.15) 0.98 (0.84-1.15) 
     
P  0.09 0.47 0.47 
     
Yogurt     
Almost never 956 1 1 1 
1-3/m 538 0.86 (0.77-0.95) 0.90 (0.81-1.00) 0.89 (0.80-1.00) 
1/wk 251 0.94 (0.81-1.07) 0.99 (0.86-1.14) 0.99 (0.86-1.13) 
≥2/wk 304 0.83 (0.73-0.95) 0.86 (0.75-0.98) 0.86 (0.75-0.98) 
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P  0.13 0.19 0.19 
     
Cottage/ricotta cheese    
Almost never 933 1 1 1 
1-3/m 742 0.94 (0.86-1.04) 0.98 (0.89-1.08) 0.98 (0.89-1.08) 
1/wk 216 0.94 (0.81-1.09) 0.99 (0.85-1.15) 0.99 (0.85-1.15) 
≥2/wk 158 1.04 (0.88-1.23) 1.08 (0.91-1.28) 1.08 (0.91-1.28) 
     
P  0.92 0.61 0.61 
     
Cream cheese     
Almost never 1109 1 1 1 
1-3/m 654 0.93 (0.84-1.02) 0.96 (0.87-1.05) 0.96 (0.87-1.05) 
1/wk 172 0.89 (0.76-1.05) 0.94 (0.80-1.10) 0.94 (0.80-1.10) 
≥2/wk 114 0.94 (0.78-1.14) 0.97 (0.80-1.18) 0.97 (0.80-1.18) 
     
P  0.31 0.47 0.48 
     
Low-fat cheese     
Almost never 1551 1 1 1 
1-3/m 85 1.08 (0.86-1.36) 1.06 (0.84-1.34) 1.06 (0.84-1.34) 
1/wk 111 1.03 (0.85-1.26) 1.03 (0.84-1.25) 1.03 (0.84-1.25) 
≥2/wk 214 0.98 (0.86-1.12) 1.00 (0.87-1.15) 1.00 (0.87-1.15) 
     
P  0.97 0.79 0.78 
     
High-fat cheese     
Almost never 721 1 1 1 
1-3/m 169 0.94 (0.79-1.12) 0.93 (0.77-1.11) 0.93 (0.77-1.11) 
1/wk 274 1.05 (0.92-1.21) 1.07 (0.93-1.23) 1.07 (0.93-1.23) 
≥2/wk 714 1.02 (0.92-1.12) 1.07 (0.97-1.19) 1.07 (0.97-1.19) 
     
P  0.99 0.46 0.44 
     
Butter     
Almost never 1284 1 1 1 
1-3/m 420 1.02 (0.91-1.14) 1.00 (0.89-1.11) 1.00 (0.89-1.11) 
≥1/wk 345 1.01 (0.89-1.14) 0.97 (0.86-1.09) 0.97 (0.86-1.09) 
     
 P  0.92 0.78 0.78 
aMV1 model adjusted for age (months; continuous), pack-years of smoking (0-10, 11-20, or 
≥21), BMI (in kg/m2; <18.5, 18.5 to <25, 25 to <30, or ≥30), age at menarche (continuous), 
parity (nulliparous, 1-2, or ≥3), breastfeeding duration (continuous), percentage of total kcal 
from vegetable protein (quintiles 1-3 or 4+5), alcohol intake (<10 or ≥10 g/d), and current 
multivitamin use (yes or no).  
bMV2 model adjusted for MV1 covariates + total vitamin D intake (continuous) and total 
calcium intake (continuous).  
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